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Introduction. 
 
Palmitoylethanolamide (PEA), a member of fatty-acid ethanolamide 
family, is an endogenous neuromodulator with a broad spectrum of 
pharmacological properties, including analgesic (Calignano et al., 1998, 
2001), anti-inflammatory (Costa et al., 2002; D’Agostino et al., 2007), 
anticonvulsant (Lambert et al., 2001) and antiproliferative (Di Marzo et al., 
2001) effects. 
Less investigated are the functions of PEA in the central nervous system 
(CNS), where PEA is present in detectable levels (Cadas et al., 1997), 
showing diurnal variation (Rodriguez et al., 2006). Despite its molecular 
target remain debate, PEA failed to exert its analgesic and anti-
inflammatory properties in mice lacking peroxisome proliferator-activated 
receptor alpha (PPAR-α) (LoVerme et al., 2005; D’Agostino et al., 2007). 
Although PPAR-α is a well characterized transcription factor (Lemberger et 
al., 1996), it seems to be pivotal for other effects not strictly related to its 
transcriptional activity, such as the effect on calcium-activated K+ channels, 
mediating rapid analgesia (Lo Verme et al., 2006). Likewise PEA, PPAR-α 
has been localized in discrete areas of the CNS with a peculiar distribution 
(Kainu et al., 1994; Moreno et al., 2004; Benani et al., 2004), although its 
role in these areas is unclear and poorly defined. 
In the last ten years it has emerged that neurosteroids are strongly involved 
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in several physiological cognitive and emotive functions of the CNS (Jung-
Testas and Baulieu, 1998). Neurosteroids are known to exert several rapid 
effects, including modulation of hypnosis, through activation of GABAA 
receptors, these studies have been mainly conducted with the action of 
pregnenolone-like neuroactive steroid (Mendelson et al., 1987), and 
metyrapone, a blocker of the enzyme 11β-hydroxylase, which is essential 
for the biosynthesis of corticosteroids (Burade et al., 1996). Keller et al. 
(2004) have shown that 5α-reduced neurosteroids act on GABAA, as well 
as peripheral benzodiazepine receptor (PBR), modulating the GABA-
induced Cl- currents that result in neuron hyperpolarization. Among 5α-
reduced neuroactive steroids, the 3α-hydroxy-5α-pregnan-20-one 
(allopregnanolone, ALLO) displays anxiolytic, sedative, analgesic and 
anaesthetic properties (Rupprecht et al., 2001), causing a great 
pharmacological interest. The main pharmacological properties above 
reported are shared with those of PEA. 
Particularly, it was previously reported that N-acylethanolamines of 
unsaturated fatty acid (N-linoleoyl-, N-oleoyl-) and of saturated fatty acid 
(PEA), significantly prolonged pentobarbital-induced hypnosis in mice 
(Watanabe et al., 1999). 
Here, we hypothesize that exogenous administration of PEA, through a 
PPAR-α-dependent mechanism, participates in neurosteroid formation 
increasing their levels and leading to a positive modulation of GABAA 
receptor. For this aim, we study the effect of PEA in vitro using C6 glioma 
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cell line and primary murine astrocytes, which, as other glial cells and 
neurons, have the enzymatic machinery for de novo synthesis of 
neurosteroids and in vivo using pentobarbital induced LORR duration and 
EEG recordings in mouse. In particular, Fast Fourier Transformer (FFT) 
power spectral analysis was applied to reveal the time change of slow wave 
activity in the EEG, which would provide some quantitative measures of 
LORR EEG. 
The demonstration of the capacity of a neural centre to synthesize 
neurosteroids requires the localization in that centre of active forms of key 
steroidogenic enzymes, and local increase of neurosteroids. Therefore, we 
evaluated the ALLO content and the expression of StAR and P450scc, two 
proteins implicated in the early step of neurosteroidogenesis in 
mitochondrial fraction, supernatant and brainstem. As well known, this area 
serves integrative functions, including, pain sensitivity control, alertness, 
and consciousness, and shows appreciable and functional levels of PEA 
(Petrosino et al., 2007; Melis et al., 2008), as well as of PPAR-α (Moreno et 
al., 2004; Melis et al., 2008). 
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Discovery of PEA. 
 
The discovery of naturally occurring fatty acid ethanolamides (FAEs) (fig. 
1) stems from an interesting clinical finding in the early 1940s, when 
investigators noted that supplementing the diets of underprivileged children 
with dried chicken egg yolk prevented recurrences of rheumatic fever, 
despite continued streptococcal infections (Coburn and Moore, 1943). 
 
 
 
Fig. 1. Chemical structures of various fatty acid ethanolamides, palmitoylethanolamide, 
oleoylethanolamide, and arachidonoylethanolamide (anandamide). 
 
 
  10 
In a continuation of this research, it was demonstrated that lipid fractions 
purified from egg yolk (Coburn et al., 1954; Long and Martin, 1956), as 
well as peanut oil and soybean lecithin (Long and Miles, 1950), exerted 
anti-allergic effects in the guinea pig (see fig. 2 for a timeline of events). 
Soon thereafter, PEA (N-(2-hydroxyethyl)hexadecanamide, N-
palmitoylethanolamide, LG 2110/1) was isolated as the agent responsible 
for these anti-inflammatory properties (Kuehl et al., 1957). This work 
ultimately led to its identification in mammalian tissues in 1964 (Bachur et 
al., 1965). 
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Fig. 2. PEA: a historical perspective. The discovery of PEA dates back to 1957, when it was 
found to be the active anti-inflammatory constituent of egg yolk. PEA was identified in 
mammalian tissues in 1965 and was used in the clinic during the 1970s for the treatment of 
influenza. PEA is currently used as a veterinary anti-inflammatory medication as part of a 
nutritional composition sold under the trade name of Redonyl®. 
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Pharmacological properties of PEA. 
 
Since the discovery of anandamide, the properties of PEA have been 
explored with growing interest (fig. 3). 
 
 
 
Fig. 3. Pharmacological consequences of PEA administration. PEA produces a broad range of 
actions including anti-inflammation, analgesia, neuroprotection, and anticonvulsant activity. It 
may also exert prophylactic actions towards respiratory tract infections. 
 
 
In addition to its known anti-inflammatory activity, PEA also produces 
analgesia (Calignano et al., 1998, 2001; Jaggar et al., 1998), anti-epilepsy, 
and neuroprotection (Franklin et al., 2003; Lambert et al., 2001; Sheerin et 
al., 2004; Skaper et al., 1996). PEA also inhibits food intake (Rodríguez de 
Fonseca et al., 2001), reduces gastrointestinal motility (Capasso et al., 
2001) and cancer cell proliferation (De Petrocellis et al., 2002; Di Marzo et 
al., 2001), and finally protects the vascular endothelium in the ischemic 
heart (Bouchard et al., 2003). 
Following the early experiments in the 1950s, a series of more recent 
studies has shown that PEA inhibits mast cell degranulation (Aloe et al., 
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1993; Mazzari et al., 1996) and pulmonary inflammation in mice 
(Berdyshev et al., 1998). These effects have been tentatively linked to 
reduced nitric oxide production by macrophages (Ross et al., 2000) and/or 
neutrophil influx (Farquhar-Smith and Rice, 2003). For example, in one 
study, animals treated with PEA for 3 days (10 mg kg-1, orally, once daily) 
following a carrageenan-induced inflammatory insult displayed 
significantly lower levels of inducible nitric oxide synthase (iNOS) and 
cyclooxygenase (COX-2) (Costa et al., 2002) a genomic action reminiscent 
of steroidal anti-inflammatory drugs. Other studies have demonstrated that 
PEA reduces inflammation in a matter of hours (Conti et al., 2002; 
LoVerme et al., 2005), implying that a non-genomic mechanism of action 
may also exist. 
Broad-spectrum analgesia by PEA has been documented in a variety of 
pain models. PEA reduces pain behaviors elicited by formalin (Calignano 
et al., 1998; Jaggar et al., 1998), magnesium sulfate (Calignano et al., 
2001), carrageenan (Conti et al., 2002; Mazzari et al., 1996), nerve growth 
factor (Farquhar-Smith and Rice, 2003), and turpentine (Farquhar-Smith 
and Rice, 2001; Jaggar et al., 1998). 
Moreover, PEA was found to inhibit hyperalgesia after sciatic nerve 
ligation, a model of neuropathic pain (Helyes et al., 2003). Because PEA-
induced analgesia is rapid and precedes the compound’s anti-inflammatory 
actions, it has been suggested that PEA may function as an endogenous 
regulator of nociception (Calignano et al., 1998). 
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Less understood are the functions of PEA in the central nervous system 
(CNS), where PEA is present at high levels (Cadas et al., 1997). Increasing 
evidence points to an antiepileptic and neuroprotective action of PEA 
(Lambert et al., 2001; Sheerin et al., 2004). For example, in one study, 
intraperitoneal administration of the compound was shown to inhibit 
electroshock-induced and chemically induced seizures with a half-
maximally effective dose (ED50) of 9 mg/kg, i.p. (Lambert et al., 2001). 
Other neuroprotective actions have also been reported; for example, in a 
separate study, PEA dose-dependently protected cultured mouse cerebellar 
granule cells from glutamate toxicity (Skaper et al., 1996). In yet another 
study, PEA reduced histamine-induced cell death in hippocampal cultures 
(Skaper et al., 1996). 
Finally, PEA was more recently shown to enhance microglial cell motility 
(Franklin et al., 2003). 
 
 
PEA biosynthesis and inactivation. 
 
Unlike classical neurotransmitters and hormones which are stored in and 
released from intracellular secretory vesicles, the production of FAEs 
occurs through on-demand synthesis within the lipid bilayer (Cadas et al., 
1996; Schmid et al., 1990). In mammalian tissues, two concerted and 
independent biochemical reactions are responsible (fig. 4). 
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Fig. 4. PEA biosynthesis and inactivation. The biosynthesis of PEA occurs in a two steps. (1) 
The calcium- and cAMP-dependent transfer of palmitic acid from phosphatidylcholine (PC) to 
phosphatidylethanolamine (PE) to form N-acylphosphatidylethanolamine (NAPE). (2) The 
cleavage of NAPE to release PEA, mediated by a NAPE-specific phospholipase D (PLD). (3) 
PEA is hydrolyzed by fatty acid amide amidohydrolase (FAAH) or PEA-preferring acid amidase 
(PAA) to form palmitic acid and ethanolamine. 
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The first is the transfer of a fatty acid from membrane-bound phospholipids 
to phosphatidylethanolamine (PE), catalyzed by a calcium ion and cyclic-
AMP regulated N-acyltransferase (NAT), to form the FAE precursor N-acyl 
phosphatidylethanolamine (NAPE). Different FAE precursors are generated 
according to which fatty acid is initially transferred to PE (i.e., the initial 
transfer of palmitic acid will yield a PEA precursor, while that of 
arachidonic acid will yield an anandamide precursor). The second step in 
FAE synthesis is the cleavage of membrane-bound NAPE to release free 
PEA, which is mediated by a NAPE-specific phospholipase D (PLD). This 
lipid hydrolase shares little sequence homology to other members of the 
PLD family and recognizes multiple NAPE species, producing PEA along 
with other FAEs (Okamoto et al., 2004). 
Alternatively, a separate mechanism of synthesis has been proposed 
involving a similar two-step reaction: (1) the hydrolysis of NAPE to N-
palmitoyl-lysoPE (lyso-NAPE) by soluble phospholipase A2 (sPLA2) and 
(2) the subsequent cleavage of lyso-NAPE by a lysophospholipase D (lyso-
PLD) (Natarajan et al., 1984). The activities of these two enzymes are 
highest in the stomach, brain, and testis (Sun et al., 2004). The relative 
contribution of each of these synthetic pathways is unknown at present. 
PEA inactivation primarily consists of its intracellular hydrolysis by lipid 
hydrolases (Fig. 4) (Schmid et al., 1985). One of these enzymes, called 
fatty acid amide hydrolase (FAAH), has been molecularly cloned (Cravatt 
et al., 1996) and extensively characterized (Bracey et al., 2002), and 
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selective inhibitors that block its activity in vivo have been developed 
(Kathuria et al., 2003). A second enzyme, referred to as PEA-preferring 
acid amidase (PAA), has also been identified (Ueda et al., 2001). 
FAAH, a membrane-bound intracellular serine hydrolase, for which PEA is 
an excellent substrate (Désarnaud et al., 1995; Hillard et al., 1995; Ueda et 
al., 1995), is present in all mammalian tissues, but is particularly abundant 
in brain and liver (Cravatt and Lichtman, 2002). In fact, mice lacking the 
faah gene have dramatically reduced PEA hydrolysis and increased PEA 
levels in brain and liver tissues (Cravatt et al., 2004; Lichtman et al., 2002; 
Patel et al., 2004). In contrast to FAAH, PAA activity is most abundant in 
the rodent intestine, spleen, and lung (Ueda et al., 2001). PAA recognizes 
all FAEs, suggesting that it may play a broad role in the deactivation of 
these compounds by intact cells; however, in the presence of detergent, this 
activity displays a marked preference for PEA as a substrate (Ueda et al., 
2001). 
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The PEA receptor. 
 
Despite its potential clinical significance, the cellular receptor responsible 
for the actions of PEA has long remained unidentified, and a great deal of 
controversy has surrounded its identity. The structural and functional 
similarities between anandamide and PEA first suggested that these two 
lipid mediators might share the same receptor. In support of this idea, PEA 
was initially reported to displace the binding of the high-affinity 
cannabinoid agonist [3H]WIN55,212-2 with a half-maximal inhibitory 
concentration (IC50) of 1.0 nM from RBL-2H3 cell membranes, which are 
known to express CB2 mRNA (Facci et al., 1995). However, these results 
have not been subsequently replicated (Jacobsson and Fowler, 2001; 
Lambert et al., 2002; Lambert and Di Marzo, 1999; Showalter et al., 1996; 
Sugiura et al., 2000) and it is now generally accepted that PEA does not 
bind to CB2 receptors. Adding to the PEA mystery, the CB2 
antagonist/inverse agonist SR144528 inhibits many, but not all, of the 
pharmacological actions of PEA (Calignano et al., 1998, 2001; Conti et al., 
2002; Jaggar et al., 1998). In particular, the analgesic actions of PEA are 
blocked by SR144528 (Calignano et al., 1998; Farquhar-Smith and Rice, 
2001, 2003; Helyes et al., 2003), whereas its anti-peristaltic effects are not 
(Capasso et al., 2001). Further confounding the issue, it appears that the 
anti-inflammatory actions of PEA are only sensitive to SR144528 in acute 
models of inflammation (Conti et al., 2002; Costa et al., 2002; LoVerme et 
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al., 2005). 
In light of these apparent discrepancies, several possible scenarios have 
been proposed to describe the mechanism of action of PEA (fig. 5). 
 
 
 
Fig. 5. Proposed mechanisms of action for PEA. PEA may exert its effects through an unknown 
receptor, which may either be sensitive to SR144528 (1) or engage CB2 receptors as 
downstream effectors (2). (3) PEA may act as an “entourage compound”, effectively inhibiting 
FAAH activity, and thus increasing local anandamide levels (see text for further details). 
 
The first possibility is that PEA binds to an unidentified receptor for which 
SR144528 is a functional antagonist (i.e., a compound that either directly 
interacts with the receptor, or indirectly blocks a downstream effector of 
this receptor (CB2 receptors)). A second possibility is that PEA acts 
through a so-called “entourage effect” (Ben-Shabat et al., 1998; Lambert 
and Di Marzo, 1999). According to this theory, PEA may increase 
anandamide levels in tissues by competing with this compound for FAAH-
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mediated hydrolysis, resulting in a potentiation of anandamide’s actions. 
However, “entourage effects” have only been observed in vitro. In contrast, 
administration of PEA in vivo has the opposite result of decreasing 
endogenous anandamide levels (LoVerme et al., 2005). Finally, Di Marzo 
et al. (2001) suggested that in human breast cancer cells, PEA may work by 
inhibiting FAAH expression, which should lead to an increase in 
anandamide levels. This hypothesis does not account, however, for the very 
rapid actions of PEA, which occur within minutes of its administration. 
 
 
PEA: An Independent Endocannabinoid? 
 
Results showing that PEA interacts with a distinct non-CB1/CB2 receptor 
suggest that this lipid might constitute a unique “parallel” endocannabinoid 
signaling system. Providing support to this concept is the evidence that 
PEA production and inactivation can occur independently of AEA and 2-
AG production and inactivation. Specifi cally, in rodent cortical neurons, 
general activity-dependent production of AEA, 2-AG, and PEA occurs 
concomitantly (Di Marzo V et al., 1994; Cadas et al., 1997; Hansen et al., 
1997).  Yet, subsequent studies showed that 2-AG production can be 
increased independently when N-methyl-D-aspartate (NMDA) receptors 
are activated, while increased AEA and PEA production requires addition 
of carbachol (Stella and Piomelli, 2001). A more detailed pharmacological 
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study showed that activation of nicotinic receptors increases AEA 
production, while activation of muscarinic receptors increases PEA 
production. Thus, although biosynthesis of all endocannabinoids in this 
model system is contingent on NMDA-receptor occupation, increased AEA 
production requires the co-activation of α7 nicotinic receptors, while 
increased PEA production requires the co-activation of muscarinic 
receptors. This finding suggests that glutamate and acetylcholine may elicit 
the biosynthesis of different endocannabinoids depending on the 
complement of cholinergic receptors expressed in their target neurons. 
Additional evidence for independent production of AEA, 2-AG, and PEA 
comes from experiments performed on mouse astrocytes in culture. In this 
model, the calcium ionophore ionomycin and the peptide endothelin-1 
increase the production of both AEA and 2-AG, while PEA levels remain 
unchanged (Walter et al., 2002; Walter and Stella, 2003). The notion that 
PEA might be independently produced also holds true in vivo (Franklin et 
al., 2003). For example, in the case of focal cerebral ischemia, PEA levels 
in ischemic cerebral cortex increase ~25-fold compared with sham-
operated animals, while AEA levels increase by barely 3-fold and 2-AG 
levels remain unchanged. 
Novel evidence shows that PEA inactivation can also occur independently 
from that of AEA and 2-AG. The laboratory of Natsuo Ueda discovered the 
existence of a unique enzyme capable of hydrolyzing PEA to much greater 
extent than AEA and 2-AG. The original observation was obtained with 
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homogenates prepared from human megakaryoblastic cells (CMK), in 
which AEA hydrolysis occurred with low activity and a strikingly different 
pH profi le from that of FAAH (Ueda et al., 2001). 
Specifically, while FAAH is known to maximally hydrolyze AEA at pH 9 
(with this activity dropping by 70% at pH 5), CMK cells were shown to 
maximally hydrolyze AEA at pH 5 (with this activity dropping by 95% at 
pH 9). Using an elegant 4-step purifi cation approach, Ueda and colleagues 
were able to purify this novel enzymatic activity by 760-fold, obtain partial 
protein sequence, and clone a cDNA encoding this protein, which was 
named N-acylethanolamine-hydrolyzing acid amidase (NAAA) (Tsuboi et 
al., 2005). 
When assessing its substrate specifi city, it became clear that this enzyme 
preferred PEA over AEA (having hydrolytic activities toward these 
substrates of 8 and 0.25 nmol/min/mg, respectively). Besides a distinct pH 
profi le and substrate specificity, NAAA has additionally very interesting 
properties. It is highly expressed in spleen and thymus, as well as in 
macrophages homing to the lungs and small intestine, highlighting its 
potential importance in regulating PEA signaling in the context of 
immunobiology. Here, it should be emphasized that NAAA expression and 
activity are quite low in healthy brain (Tsuboi et al., 2005). 
The laboratory of Didier Lambert developed a competitive inhibitor of 
NAAA, N-cyclohexanecarbonylpentadecylamine, which has an IC50 of 5 
µM and is inactive against FAAH at 100 µM (Ueda et al., 2005). 
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When considering that methyl arachidonoylfluorophosphonate (MAFP) and 
URB597 inhibit FAAH with nanomolar IC50s and are both inactive against 
NAAA at a concentration of 1 µM, experiments designed to use these 
compounds in combination may be useful to distinguish the biological 
importance of either PEA or AEA hydrolysis in various biological 
responses (Sun et al., 2005; Ueda et al., 2005). 
 This series of studies raises many fascinating questions: for example, 
“What is the subcellular location of NAAA and does it differ from FAAH? 
”The pH profile of NAAA is quite intriguing. With maximal NAAA 
activity occurring at pH 5 and only 10% of this activity remaining at pH 7 
(i.e., the cytosolic pH), one wonders if NAAA might be active only in 
lysosomes. Accordingly, NAAA-GFP (green fluorescent protein) fusion 
protein localized to lysosome-like vesicles (Tsuboi et al., 2005). 
This result is quite interesting when considering that FAAH is also 
abundant in intracellular organelles such as mitochondria and the smooth 
endoplasmic reticulum (Gulyas et al., 2004). 
Clearly, elucidating the exact biological role of NAAA will be facilitated 
by genetic studies similar to those performed on FAAH. Finally, while AEA 
and 2-AG hydrolysis give rise to new bioactive lipids (ie arachidonic acid 
and eicosanoids), PEA hydrolysis gives rise to 2 relatively inactive 
products, palmitic acid and ethanolamine, suggesting that the role of 
NAAA is to truly stop biological responses initiated by increases in PEA 
production. 
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Acylethanolamides and PPAR-α. 
 
The first evidence of acylethanolamide interactions with PPARs came in 
2002 in a study by Kozak et al., who showed that lipoxygenase (LOX) 
metabolism of the endocannabinoid, 2-arachidonoylglycerol (2-AG), 
produced a metabolite (15-hydroxyeicosatetraenoic acid glyceryl ester, 15-
HETE-G, 1-10 mM) that increased the transcriptional activity of PPAR-α, 
as shown in a reporter gene assay. In 2003, it was then shown by Fu et al. 
that oleoylethanolamide (OEA, 0.1-10 µM) bound to and increased the 
transcriptional activity of PPAR-α, a finding later confirmed by Sun et al. 
(2006). OEA is a naturally occurring amide of ethanolamine and oleic acid, 
produced through biosynthetic pathways similar to those of anandamide 
but, despite the structural and metabolic similarities with anandamide, OEA 
does not bind to cannabinoid receptors. Fu et al. (2003) showed that the 
appetite-suppressing and weight-reducing effects of OEA (10 mg kg-1) 
were absent in PPAR-α knockout mice, and that daily treatment with OEA 
(5 mg kg-1, 2 weeks) reduced serum cholesterol levels in rat and mouse 
models of obesity. Guzman et al. (2004) then showed that the stimulatory 
effect of OEA (5 mg kg-1, 4 weeks) on lipolysis in vivo was absent in 
PPAR-α knockout mice, and that a single dose of OEA (10 mg kg-1) in rats 
increased the mRNA levels of a number of PPAR- α target genes (PPAR-α, 
fatty acid-binding protein and uncoupling protein 2). Further work has now 
shown that the anti-inflammatory effects of OEA in 12-O-tetradecanoyl-
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phorbol-13-acetate-induced oedema in mice (LoVerme et al., 2005) and the 
neuroprotective effects of OEA in a mouse model of cerebral artery 
occlusion (Sun et al., 2006) were also absent in PPAR-α knockout mice. 
Together, these studies suggest that many of the physiological responses to 
OEA are mediated by PPAR-α activation. A number of structural analogues 
of OEA have also been shown to have a high affinity for PPAR-α, with 
similar reductions in food intake when administered in vivo (Astarita et al., 
2006). 
Like OEA, another fatty acid ethanolamide, palmitoylethanolamide (PEA) 
is reported to have actions that cannot be attributed to traditional 
cannabinoid receptor sites of action. After demonstrating that OEA, which 
is structurally related to PEA, activates PPAR-α (Fu et al., 2003), Lo Verme 
et al. (2005) went on to show that PEA (1-30 µM) similarly activates 
PPAR-α transcriptional activity, causing anti-inflammatory actions in both 
12-O-tetradecanoylphorbol-13-acetate-induced and carrageenan-induced 
oedema that were absent in PPAR-α knockout mice (at 10 mg kg-1; 
LoVerme et al., 2006). Further studies showed that PEA (50 µg, intraplantar 
injection) caused analgesic effects in vivo in several models of pain 
behaviour, which were also absent in PPAR-α knockout mice (LoVerme et 
al., 2006). Other acylethanolamides shown to activate and bind to PPAR-α 
include anandamide, noladin ether and virodhamine (Sun et al., 2006), 
suggesting that PPAR-α activation is common to all acylethanoamides, or 
at least all those tested to date. It is of note that the concentrations of 
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acylethanolamides required to activate PPARs are in the same range as 
those reported for fatty acids (Kliewer et al., 1997). However, it has not yet 
been established whether combinations of fatty acids/endocannabinoids (as 
would occur intracellularly) may act synergistically at PPARs. 
The majority of research to date has focused on the effects of 
acylethanolamides on PPAR-α, and the effects of synthetic or 
phytocannabinoids at this receptor are yet to be investigated. The synthetic 
CB1/CB2 agonist, WIN55212-2, is reported to bind to and increase the 
transcriptional activity of PPAR-α (Sun et al., 2006), although whether 
WIN55212-2 causes similar effects (anti-inflammatory actions, anorexia, 
lipolysis and analgesia) through this site, as reported for OEA and PEA, 
remains to be established. 
 
 
Peroxisome proliferator-activated receptors. 
 
PPARs belong to the nuclear hormone receptor superfamily and three 
different subtypes have been identified, PPAR-α, PPAR-β (also called 
PPAR-δ or β/δ, NUC-1 or FAAR), and PPAR-γ and these receptors have 
been found in teleosts, amphibians, rodents, and humans (Dreyer et al., 
1992; Schmidt et al., 1992; Sher et al., 1993; Kliewer et al., 1994; Greene 
et al., 1995; Escriva et al., 1997; Fajas et al., 1998). Alternate promoter 
usage and splicing occur and three PPAR-γ variants have been 
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characterized, PPAR-γ 1, 2 and 3. PPAR-γ 2 has 30 additional N-terminal 
amino acids. A third promoter in the human sequence encodes a protein, 
PPAR-γ 3 (Fajas et al., 1998). The PPAR subtypes are encoded by distinct 
single-copy genes and have a structure characteristic of the nuclear 
hormone receptors. Each receptor has an N-terminal “A/B” domain that has 
a ligand-independent activation function and is poorly conserved between 
the isoforms. The “C” domain encodes the DNA binding region of the 
receptor, is highly conserved, includes two zinc-finger-like structures with 
α-helical DNA binding motifs and is followed by the “D” or hinge region. 
The C-terminal ligand binding domain (LBD), the “E/F” domain, contains 
the ligand-dependent activation function 2 (AF-2) and is also important for 
RXR heterodimerization. The ligand-binding domains (LBD) are highly 
conserved and the mouse PPAR-γ 2 LBD sequence is 70% and 68% similar 
to mouse PPAR-β and PPAR-α LBDs, respectively (Escher and Wahli, 
2000). The rat and mouse PPAR-α proteins share 92% identity with the 
human receptor. The rat and mouse PPAR-β are 91% and 92% homologous 
with the human PPAR-β amino acid sequence. Rat and mouse PPAR-γ 1 
and 2 have 95–98% homology with the human receptor (Borel et al., 2008). 
PPARs regulate gene expression by binding to specific DNA sequences, 
peroxisome proliferator response elements (PPRE), in the promoter regions 
of target genes (fig. 6). 
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Fig. 6. Structure of PPARs. (A) Schematic view of the domain organization of PPARs. Structural 
and functional domains are depicted.The A/B domain contains the activation function 1 (AF-1), 
which has a ligand-independent transcriptional activity. The C domain corresponds to the DNA 
binding domain (DBD). The E/F domain contains the ligand binding domain (LBD) and carries 
the activation function 2 (AF-2), which has a ligand-dependent transcriptional activity. The 
percentage of amino acid identity of the DBDs and LBDs of human PPAR-β and PPAR-γ 
compared with PPAR-α is indicated. (B) Three-dimensional structure of ligand binding domains 
of PPARs. A comparison of the X-ray crystal structures of PPAR-α (red worm), PPAR-γ (yellow 
worm) and PPAR-β (green worm) is shown. Each PPAR is complexed to a high-affinity ligand 
(not pictured). PPAR-α and PPAR-γ are shown associated to LXXLL peptides (purple worms), 
the signature motif of the receptor coactivators. For each PPAR, the solvent-accessible ligand 
binding pocket is displayed as an off-white surface. 
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The initial characterization of the PPRE identified it as a direct repeat 1 
motif (DR1), which consists of two copies of a core motif sequence, 
AGGTCA, separated by one nucleotide. The determinants of the PPRE 
differ from those for response elements of other members of the TR/RAR 
class, however there is considerable variation in the sequences with which 
PPARs interact (Keller et al., 2000). Prior to DNA binding PPAR forms a 
heterodimer with the retinoid X receptor (RXR), another member of the 
nuclear receptor super family (Tan et al., 2005; Tien et al., 2006). The 
endogenous ligand for RXR is 9-cis-retinoic acid and RXR is a partner for 
several other nuclear receptors (retinoic acid receptor, thyroid hormone 
receptor, and vitamin D receptor). Upon ligand binding, conformational 
changes are induced in the LBD that involve the AF-2 C-terminal helix and 
the PPAR-RXR heterodimer subsequently interacts with the PPRE, recruits 
co-activators/co-factors, and activates transcription (Tan et al., 2005; Tien 
et al., 2006; Zoete et al., 2007). The co-activators known to interact with 
the complex include the steroid receptor co-activator 1 (SRC-1) which 
interacts with the E/F and A/B domains of all three isoforms, and CREB- 
binding protein (CBP/p300) which associates with the helical AF region of 
PPAR-α and γ (fig. 7). 
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Fig. 7. The most recognized mechanism by which peroxisome proliferators regulated gene 
expresssion is through a PPAR/RXR heterodimeric complex binding to a peroxisome 
proliferator-response element (PPRE) (classical mechanism). However, there are the possibility 
of several variations on this theme: 1). The peroxisome proliferator interacts with PPAR that 
preexists as a DNA complex with associated corepressors proteins. The interaction with ligand 
causes release of the corepressor and association with a coactivator, resulting in the classical 
  31 
mechanism. 2). The peroxisome proliferator interacts with PPAR as a soluble member of the 
nucleus. The binding of ligand results in RXR heterodimerization, DNA binding and coactivator 
recruitment. 3). In this scenario, PPAR exists in the cytosol, perhaps complexed to heat shock 
protein 90 and/or other chaperones. Binding of peroxisome proliferator causes a conformational 
change and translocation into the nucleus. Scenarios 4 and 5 require regulation of gene 
expression via non-classical mechanisms: 4). PPAR is capable of interacting with, and forming 
DNA binding heterodimers with, several nuclear receptors including the thyroid hormone 
receptor. The binding site for this non-RXR heterodimer need not be the classic DR-1 motif 
found in the PPRE. 5). PPAR may participate in the regulation of gene expression witout 
binding to DNA. By association with transcription factors such as c-jun or p65, PPAR 
diminishes the ability of AP1 or NFB to bind to their cognate DNA sequences, respectively. 
Also shown in this scheme are two means to modify the peroxisome proliferator response. Most 
importantly, growth factor signaling has a pronounced affect on PPAR via post-translational 
modification. PPAR is a phosphoprotein and its activity is affected by insulin. Several kinase 
pathways affects PPAR-α's activity, although the specific kinases and phosphorylation sites have 
not been conclusively determined. 
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Other co-activators are PPAR-γ co-activator 1 (PGC-1) and PGC-2 which 
interact with PPAR-γ, the ubiquitously expressed PPAR binding protein 
(PBP/TRAP220/DRIP230) which interacts with PPAR-α and γ, the 
androgen receptor associated protein 70 (ARA70), and receptor interacting 
protein (RIP140) an inhibitor of PPAR-α and γ activity. The interactions 
may also result in release of co-repressors, such as the silencing mediator 
for retinoid and thyroid hormone receptors (SMRT) and the nuclear 
receptor corepressor (NCoR) which dissociates from PPAR-α and γ in the 
presence of agonists. As can be deduced from the names of some of these 
co-factors, the same proteins interact with other steroid hormone receptors 
(glucocorticoid receptor, thyroid hor- mone receptor, estrogen receptor, 
vitamin D receptor, retinoic acid receptor, etc.). PPARs can regulate gene 
expression via multiple modes of action (Tan et al., 2005). PPARs may 
repress expression of genes by interacting with co-repressors and with 
RXR to suppress expression of target genes and this repression could be 
released upon activation with either a PPAR or an RXR ligand followed by 
recruitment of co-activators (Tan et al., 2005; Tien et al., 2006; Zoete et al., 
2007). PPARs may also influence gene expression through interactions 
with or modulation of other transcription factors and cell signaling 
pathways (Glass and Ogawa, 2006). 
A number of endogenous ligands have been identified for each PPAR 
isoform and include long chain fatty acids, polyunsaturated fatty acids such 
as linoleic and arachidonic acid, saturated fatty acids such as 
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palmitoylethanolamide, and eicosanoids. A variety of synthetic ligands 
have been developed for pharmaceutical purposes, including the fibrate 
class of hypolipidemic drugs that activate PPAR-α (clofibrate, benzafibrate, 
ciprofibrate), the anti-diabetic thiazolidinediones that activate PPAR-γ 
(rosiglitazone), PPAR-β agonists designed to treat metabolic syndrome 
(GW501516) and non-steroidal anti-inflammatory drugs (indomethacin, 
ibuprofen, fenoprofen). Other chemicals that may occur in industrial 
processes and as environmental contaminants are known to activate PPAR, 
e.g. phthalates, tri- and dichloroacetic acid, trichloroethylene, 
perfluoroalkyl acids such as PFOS and PFOA (Desvergne and Wahli, 1999; 
Escher et al., 2000; Klaunig et al., 2003; Peraza et al., 2006). Ligands may 
not be specific to a single PPAR isoform. There are examples of both 
endogenous and exogenous ligands with the ability to bind and activate 
multiple or specific isoforms (Zoete et al., 2007). However, it is also 
important to note that there are PPAR-dependent effects which require 
expression of the receptor, but for which ligand is not required. 
Genes regulated by PPAR isoforms are involved in important physiological 
processes that have impacts on lipid homeostasis, inflammatory responses, 
adipogenesis, reproduction, wound healing, and carcinogenesis (Escher et 
al., 2000; Michalik et al., 2002; Mandard et al., 2004; Kilgore and Billin, 
2008). 
PPAR regulation impacts cellular processes such as proliferation, 
differentiation and cell death. PPAR-α regulates peroxisome proliferation, 
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lipid catabolism, inflammatory responses, skin wound healing, inhibition of 
arachidonic acid metabolism and inhibition of ureagenesis. PPAR-β 
activation influences cell proliferation, myelination, embryonic 
implantation, adipocyte differentiation, skeletal muscle fatty acid 
catabolism, glucose metabolism, inflammation, and skin wound healing. 
PPAR-γ regulates lipid storage, macrophage maturation, embryonic 
implantation, adipocyte differentiation and inflammation control. 
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Biosynthesis and actions of neurosteroids. 
 
 
Discovery and definition of neurosteroids. 
 
A major finding in the research on neuroactive steroids was the 
identification of the ability of neurons and glial cells to synthesize bioactive 
steroids, also called neurosteroids (Baulieu et al., 1999). This important 
discovery stemmed from a series of pioneer works showing the persistence 
of substantial amounts of PREG, DHEA and their sulfated derivatives in the 
rodent brain after gonadectomy and adrenalectomy (Corpechot et al., 1981 
and 1983). However, the consolidation of the concept of neurosteroids has 
required several investigations performed in various laboratories using 
different animal species (Baulieu et al., 1999; Mensah-Nyagan et al., 1999; 
Compagnone and Mellon 2000; Schumacher et al., 2003). These 
investigations, which significantly increased the basic knowledge on 
neurosteroids, have also allowed a strict definition of the term neurosteroid 
with specific identification criteria. The consensual definition that emerged 
considers these molecules as endogenous steroidal compounds synthesized 
in neurons or glial cells of the CNS and PNS. To be qualified as a 
neurosteroid, the candidate steroidal molecule must persist in substantial 
amounts in the nervous system after removal of the peripheral or traditional 
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steroidogenic glands such as the adrenals and gonads (Baulieu et al., 1999). 
Furthermore, it has been demonstrated that neurosteroids act as paracrine or 
autocrine factors, regulating the activity of classical nuclear steroid 
receptors and through the modulation of membrane receptors, including 
steroidal membrane receptors coupled to G proteins (Zhu et al., 2003a and 
b), GABAA and T-type calcium channels (Majewska, 1992; Belelli and 
Lambert, 2005; Pathirathna et al., 2005; Hosie et al., 2006) or via NMDA 
(Wu et al., 1991;  Bowlby, 1993), P2X (De Roo et al., 2003) and sigma 
(Monnet et al., 1995; Maurice et al., 2006) receptors. 
 
 
Evidence for neurosteroid biosynthesis. 
 
The demonstration of neurosteroid biosynthesis requires the observation of 
the expression and biological activity of key steroidogenic enzymes in 
nerve cells (Baulieu et al., 1999). 
Neurosteroid formation has been evidenced in the nervous system by 
various molecular and biochemical studies, which have revealed in neurons 
and/or glial cells the expression of TSPO, the steroidogenic acute 
regulatory protein (StAR) and of several key steroid-synthesizing enzymes 
such as cytochrome P450 side chain cleavage (P450scc; CYP11A), 3β-
hydroxysteroid dehydrogenase (3β-HSD), cytochrome P450c17 (P450c17; 
CYP17), 5α-reductase (5α-R), 3α-hydroxysteroid oxido-reductase (3α-
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HSOR), 17β-hydroxysteroid dehydrogenase (17β-HSD) and aromatase 
(CYP19) (Baulieu et al., 1999; Mensah-Nyagan et al., 1999; Compagnone 
and Mellon 2000; Schumacher et al., 2003). 
 
 
TSPO, StAR and cytochrome P450scc. 
 
Cholesterol conversion to PREG, the first step in the biosynthesis of all 
classes of steroid hormones (fig. 8), is catalyzed by the mitochondrial 
enzyme P450scc. However, there is a previous step that is rate limiting and 
hormonally regulated: the transfer of cholesterol from the outer to the inner 
mitochondrial membrane, where the P450scc enzyme is located. In this 
mechanism, two proteins located in the mitochondrial membranes, TSPO 
(Papadopoulos et al., 2006) and StAR (Lavaque et al, 2006), exert an active 
role. 
TSPO is expressed in the nervous system, predominantly in glial cells of 
CNS and PNS. Neural injury and different neuropathological conditions 
result in the induction of the expression of this molecule. TSPO basal 
expression is up-regulated in gliomas, in neurodegenerative disorders (e.g., 
Alzheimer’s disease), as well as in various forms of brain injury and 
inflammation induced by neurotoxins (Papadopoulos et al., 2006). 
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Fig. 8. Structure and synthesis of neurosteroids. Biosynthesis of GABA (γ-aminobutyric acid)-
modulatory neurosteroids. The pathway for the synthesis of 5α-pregnan-3α-ol-20-one (3α,5α-
THPROG) from cholesterol is shown. Also indicated is the site of action of drugs that have been 
used to evaluate the influence of endogenous 3α,5α-THPROG on inhibitory neurotransmission. 
Steroidogenic acute-regulatory protein (StAR) might interact with the mitochondrial 
benzodiazepine receptor (MBR) to facilitate the transport of cholesterol across the 
mitochondrial membrane. 3α-HSD, 3α-hydroxysteroid dehydrogenase; 3β-HSD, 3β-
hydroxysteroid dehydrogenase; 5α-DHPROG, 5α-dihydroprogesterone; P450scc, P450 side-
chain cleavage. 
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The induction of TSPO expression after injury in the CNS is mainly 
restricted to microglia and astrocytes (Kassiou et al., 2005). 
In the PNS, the expression of TSPO in Schwann cells is increased after 
nerve lesion, and return to normal levels when regeneration is completed 
(Lacor et al., 1999). 
StAR is formed as a 37-kDa protein, which is rapidly transported into 
mitochondria where it is cleaved, generating a mature 30-kDa 
intramitochondrial StARprotein that is inactive. StAR appears to be widely 
distributed throughout the brain, although different levels of expression 
have been detected between different brain areas. For instance, StAR 
expression seems to be restricted to very specific neuronal and astroglial 
populations in each brain area, although it is predominantly expressed by 
neurons (Sierra et al., 2003). In the PNS, StAR is expressed by Schwann 
cells (Benmessahel et al., 2004). Molecular cloning revealed the existence 
of a single gene encoding P450scc in the human and rat genome (Chung et 
al., 1986; Morohashi et al., 1987; Oonk et al., 1990). Immunoreactivity for 
P450scc was detected in the white matter throughout the rat brain and 
biochemical experiments have shown the conversion of cholesterol to 
PREG by primary culture of glial cells (Le Goascogne et al., 1987; Jung-
Testas et al., 1989). However, these studies, which were focused only on 
the brain, did not investigate the presence and activity of P450scc in the 
spinal cord. Initial data suggesting P450scc gene expression in the spinal 
cord were provided by Mellon and coworkers who have mainly used 
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developing rodent embryos (Compagnone et al., 1995). These authors 
reported the expression of P450scc mRNA and immunoreactivity in 
sensory structures of the PNS, including the dorsal root ganglion, the 
trigeminal and facio-acoustic preganglia, and mentioned P450scc existence 
in the rodent embryo spinal cord ventral horn as data not shown. 
Expression of this enzyme has also been located in the glial component of 
peripheral nerves (i.e., Schwann cells) (Schumacher et al., 2004). The first 
anatomical and cellular distribution of P450scc in the adult rat spinal cord 
has been provided by Patte-Mensah and coworkers (2003). The highest 
density of P450scc immunolabeling was found in superficial layers laminae 
I and II of spinal cord dorsal horn, where sensory neurons are located 
(Patte-Mensah et al., 2003). Double-labeling experiments revealed that 
most of the P450scc-positive fibers in the dorsal horn were also 
immunoreactive for microtubule-associated protein-2, a specific marker for 
neuronal fibers (Patte-Mensah et al., 2003). Motor neurons of the ventral 
horn also expressed immunoreactivity for P450scc, suggesting a possible 
role of the enzyme or its steroid products in the control of motor activity 
(Patte-Mensah et al., 2003). Moreover, P450scc immunostaining was 
detected in ependymal glial cells bordering the central canal in the spinal 
cord, an observation which suggests a possible release of neurosteroids in 
the cerebrospinal fluid and their involvement in volume transmission 
mechanisms in the CNS (Patte-Mensah et al., 2003). Furthermore, 
P450scc-immunoreactive cell bodies were localized in brainstem (fig. 9). 
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Biochemical experiments showing that homogenates from the adult rat 
spinal cord and brainstem are capable of converting cholesterol into PREG 
have demonstrated that P450scc-like immunoreactivity detected in the 
adult rat brain and spinal tissue corresponds to an active form of the 
enzyme (Patte-Mensah et al., 2003). 
 
  
 
 
Fig. 9. P450 side chain cleavage-immunoreactive cell bodies in the mice brainstem. Scale bar, 
100 µm. 
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5α-reductase. 
 
The enzyme 5α-R is responsible for the transformation of testosterone and 
PROG into DHT and DHP, respectively (fig. 8). In a similar manner, 5α-R 
converts 11-deoxycorticosterone to dihydrodeoxycorticosterone (DHDOC). 
Two isoforms of 5α-R, designated type 1 (5α-R1) and type 2 (5α-R2), have 
been cloned in humans and rats (Andersson and Russell, 1990; Andersson 
et al., 1991; Berman et al., 1993). The genes encoding 5α-R1 and 5α-R2 are 
located on chromosome 5 and 2, respectively, and the two isoenzymes have 
different optimal pH and sensitivity to substrates (Normington and Russell, 
1992; Wilson et al., 1993). In humans, the 5α-R1gene is predominantly 
expressed in the skin, notably in the pubic skin and scalp (Andersson and 
Russell, 1990; Jenkins et al., 1992). The 5α-R2 gene is mainly expressed in 
the prostate and gonads and its deletion provokes male 
pseudohermaphroditism (Andersson et al., 1991; Thigpen et al., 1993). In 
rats, 5α-R1 and 5α-R2 cDNAs have been cloned from a prostate library but 
the two genes are transcribed in distinct cells: mRNAs encoding 5α-R1 are 
found in the basal epithelial cells, while 5α-R2 mRNAs are localized in 
stroma cells (Andersson and Russell, 1990; Andersson et al., 1991; Berman 
et al., 1993). 
The expression of 5α-R in the brain has been extensively studied (Saitoh et 
al., 1982; Melcangi et al., 1993; Pelletier et al., 1994; Stoffel-Wagner, 
2003). It has been suggested that 5α-R1 essentially plays a catabolic and 
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neuroprotective role whereas 5α-R2 participates in sexual differentiation of 
the CNS; however, the neurophysiological significance of these two 
isoenzymes remains a matter of speculation (Celotti et al., 1992; Poletti et 
al., 1998 a and b; Torres and Ortega, 2003). In contrast to that observed in 
the brain, the quantity of 5α-R2 mRNAs extracted from the whole adult rat 
spinal cord is higher than that of 5α-R1 (Pozzi et al., 2003). 
Immunoreactivity for 5α-R1 and 5α-R2 has been detected in the white 
matter of the spinal cord, from the cervical to sacral regions. However, the 
intensity of 5α-R1 immunostaining was low and cell bodies as well as 
fibers containing this isoenzyme were observed mainly in the white matter 
of the cervical and thoracic segments. 5α-R2 immunofluorescence, which 
was moderate in the white matter, was intense in the dorsal and ventral 
horns of the gray matter (Patte-Mensah et al., 2004). Doubllabeling 
identification with specific markers for nerve cells revealed that the 5α-R1 
immunostaining was mainly expressed in oligodendrocytes and astrocytes 
of the white matter, whereas 5α-R2-immunolabeling colocalized with 
neurons and glial cells in the gray and white matters (Patte-Mensah et al., 
2004). The observation of a restricted localization of 5α-R1 to the spinal 
cord white matter is in agreement with its localization in myelinated 
structures of the female and male rat brain (Melcangi et al., 1988; Poletti et 
al., 1997). 
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3β-hydroxysteroid oxido-reductase. 
 
The enzyme 3α-HSOR also called 3α-hydroxysteroid dehydrogenase 
converts in a reversible manner DHT and DHP into the respective 
neuroactive steroids 3α-diol and THP (fig. 8). Similarly, DHDOC is 
converted to tetrahydrodeoxycorticosterone (THDOC). 3α-HSOR is a 
member of the aldo-keto reductase superfamily which includes aldehyde 
reductase, aldo reductase and dihydrodiol dehydrogenase (Jez et al., 1997; 
Jez and Penning, 2001). There are four human 3α-HSOR isozymes, but, to 
date, only one isoform has been cloned in rats (Pawlowski et al., 1991; 
Penning et al., 2003). 3α-HSOR enzymatic activity and its encoding mRNA 
have been detected in the brain (Krieger et al., 1984; Krieger and Scott 
1989; Khanna et al., 1995; Stoffel-Wagner, 2003). In the spinal cord, 
intense immunoreactivity for 3α-HSOR has been detected in the white and 
gray matters throughout the cervical, thoracic, lumbar and sacral regions. 
However, the highest density of 3α-HSOR-immunostaining is found in 
sensory areas of the dorsalhorn (Patte-Mensah et al., 2004). This study also 
revealed that 45% of 3α-HSOR immunofluorescence was localized in 
oligodendrocytes, 35% in neurons and 20% in astrocytes. A comparative 
analysis of 5α-R1, 5α-R2 and 3α-HSOR-positive elements in the spinal 
cord reveals three different situations: (i) cell bodies and fibers that express 
both 3α-HSOR and 5α-R; (ii) cell bodies that express either 5α-R1 or 5α-
R2 and (iii) cell bodies that express 3α-HSOR only (Patte-Mensah et al., 
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2004). Consequently, it appears that certain glial cells and neurons of the 
spinal cord contain both 5α-R and 3α-HSOR enzymatic proteins, which 
could catalyze the biochemical reductions required for the biosynthesis of 
5α/3α-reduced steroids that control, through allosteric modulation of 
GABAA receptors, neurobiological mechanisms including nociception, pain 
and locomotion (Majewska, 1992; Thomas et al., 1999; Gonzalez Deniselle 
et al., 2002; Patte-Mensah et al., 2004, 2005 and 2006). The production of 
5α/3α-reduced steroids may involve the cooperation of neurons, astrocytes 
and oligodendrocytes, which contain only one of the two enzymes, i.e., 3α-
HSOR or 5α-R. This cooperation may occur during physiological and 
pathological situations (Melcangi et al., 1998). In addition, 5α-R1 or 5α-R2 
may convert PROG or testosterone from peripheral sour ces into DHP or 
DHT, metabolites that act via genomic receptors, the existence of which 
has been demonstrated in spinal tissues (Lumbroso et al., 1996; 
Matsumoto, 1997; Labombarda et al., 2000). In a similar manner, 3α-
HSOR may convert, in the spinal cord, DHP, DHT or DHDOC into THP, 
3α-diol or THDOC, respectively, for the modulation of GABAA receptors 
(Majewska, 1992; Frye, 2001; Reddy, 2003; Lambert et al., 2003). The fact 
that the rat spinal tissue homogenates are capable of converting 
[3H]cholesterol into various metabolites including THP clearly indicates 
that 5α-R1, 5α-R2 and 3α- HSOR detected in the spinal cord correspond to 
active forms of these enzymes (Patte-Mensah et al., 2003 and 2004). The 
capability to convert PROG and testosterone into their 5α-(by 5α-
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reductase) and 5α/3α-reduced metabolites (by 3α-HSOR) is not restricted 
to CNS but is also present in peripheral nerves and in Schwann cells 
(Melcangi et al., 1990; Caruso et al., 2007). 
 
 
Neuroactive steroid 3α-hydroxy-5α-pregnan-20-one (3α,5α-THP) 
 
Neuroactive steroid 3α-hydroxy-5α-pregnan-20-one (3α,5α-THP) is a 
potent positive allosteric modulator of GABAA receptors, synthesized in 
brain, adrenals and gonads by successive metabolism of progesterone and 
5α-dihydroprogesterone (5α-DHP). Physiologically, 3α,5α-THP plays a 
vital role in stress, pregnancy and CNS neurotransmission (Hiemke et al., 
1991; Morrow et al., 1995; Concas et al., 1998). Systemic administration of 
3α,5α-THP induces anxiolysis, loss of righting reflex (hypnosis) and 
anesthesia in rats (Mok et al., 1993; Korneyev and Costa 1996; Brot et al., 
1997; Bitran et al., 2000). Recently, it was suggested that 3α,5α-THP also 
plays an important role during sleep (Damianisch et al., 2001; Muller-
Preuss et al., 2002) (fig. 10). 
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Fig. 10. A diagrammatic representation of an inhibitory synapse and the modulation of neuronal 
inhibition by locally released neurosteroids. GABA (γ-aminobutyric acid) that is released from 
vesicles rapidly activates a family of postsynaptic GABAA (GABA type A) receptors, which 
gives rise to a transient miniature inhibitory postsynaptic current (‘phasic’ response). 
Neurosteroids that are released locally from neurons or glia prolong the decay of such 
responses, thereby enhancing synaptic inhibition. In addition, certain neurons contain 
extrasynaptically-located receptors that are activated by low levels of ambient GABA to cause a 
‘tonic’ background current. This manifests under voltage-clamp as a ‘noisy’ baseline and is 
uncovered by the application of the GABAA-receptor antagonist bicuculline (Bic), which 
induces the closure of these extrasynaptic receptors. The current might have a considerable 
influence on neuronal firing and, in some neurons, is selectively enhanced by low 
concentrations of neurosteroids that have little effect on the phasic response that is mediated by 
synaptic receptors. 3α,5α-THPROG, 5α-pregnan-3α-ol-20-one; 5α-DHPROG, 5α-
dihydroprogesterone. 
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Furthermore, an active role of GABAergic neurosteroids in sleep induced 
by pentobarbital (Matsumoto et al., 1999) and muscimol (Pinna et al., 
2000) has been demonstrated. Ethanol administration produces 
neuropharmacological effects similar to GABAergic neuroactive steroids. 
Recent studies have demonstrated that acute ethanol administration 
remarkably increases plasma and cerebral cortical levels of 3α,5α-THP 
(VanDoren et al., 2000). Similarly, Barbaccia et al. (1999) showed ethanol-
induced increases in the cerebral cortical and hippocampal levels of 3α,5α-
THP and 3α,21-dihydroxy- 5α-pregnan-20-one (3α,5α-THDOC) in 
Sardanian alcohol preferring rats compared to non-alcohol preferring rats. 
This increase in the 3α,5α-THP levels induced by ethanol is sufficient to 
enhance GABA-mediated neurotransmission in the CNS (Morrow et al., 
1987 and 1990). Furthermore, prior administration of the 5v-reductase 
inhibitor finasteride, that inhibits bio- synthesis of 3α,5α-THP in brain, 
partially reduced ethanol- induced 3α,5α-THP levels (VanDoren et al., 
2000; Dazzi et al., 2002), and prevented anticon- vulsant and inhibitory 
effects of ethanol on spontaneous neural activity in medial septum/diagonal 
band of Broca neurons (VanDoren et al., 2000). Various lines of evidence 
suggest the increase in 3α,5α-THP induced by ethanol contributes to 
several behavioral effects of ethanol including anticonvulsant properties, 
loss of righting reflex (VanDoren et al., 2000), reinforcing properties  
(Janak et al., 1998), discriminative stimulus (Hodge et al., 2001), loss of 
spatial memory (Matthews et al., 2002), anxiolysis (Morato et al., 2001) 
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and antidepressant action (Hirani et al., 2002). Differential levels of 
neuroactive steroids are reported in alcoholic subjects (Romeo et al., 1996). 
The levels of plasma 3α,5α-THP and THDOC were markedly lower than 
those of control subjects during the early withdrawal phase (day 4 and 5), 
when anxiety and depression scores were higher. In contrast, 3α,5α-THP 
and THDOC plasma levels did not differ from those of control subjects 
during the late withdrawal phase when anxiety and depression scores were 
low (Romeo et al., 1996). Hence altered levels of neuroactive steroids 
might contribute to ethanol withdrawal symptoms. 
Sleep-related problems are more common among alcoholics than non-
alcoholics. During both drinking periods and withdrawal, alcoholics 
commonly experience problems falling asleep and decreased total sleep 
time (Aldrich, 1998; Ehlers, 2000), and high doses of acute ethanol 
administration can reduce the latency to induce sleep and produce loss of 
righting reflex (LORR). Acute ethanol administration acts like a hypnotic 
for insomniacs and appears to be associated with its reinforcing effects 
(Roehrs, et al., 1999). Since administration of GABAergic neuroactive 
steroid 3α,5α-THP induces sleep (Lancel et al., 1997; Muller-Preuss et al., 
2002) and ethanol administration increases 3α,5α-THP levels, it is possible 
that elevated 3α,5α-THP may contribute to loss of righting reflex induced 
by ethanol. Although loss of righting reflex does not represent natural 
sleep, it has recently been shown that the sedative-hypnotic component 
(LORR) of GABAergic drugs is mediated by GABAA receptors in an 
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endogenous sleep pathway (Nelson et al., 2002). A rapid tolerance to 
sedative–hypnotic effects develops upon chronic ethanol consumption 
(Roehrs et al., 2001). Similarly, tolerance to ethanol-induced elevation of 
3α,5α-THP in the cerebral cortex has been demonstrated following 14 days 
of ethanol consumption (Morrow et al., 2001a). 
Several studies have demonstrated that systemic administration of 3α,5α-
THP potentiates ethanol-induced LORR (Vanover et al., 1999; 
Czlonkowska et al., 2000 and 2001). We have previously shown that 
waking cerebral cortical levels of 3α,5α-THP correlate with the duration of 
ethanol-induced LORR (VanDoren et al., 2000). However, the role of 
3α,5α-THP in the hypnotic effects of ethanol is controversial because there 
are equivocal reports on the effect of 3α,5α-THP biosynthesis inhibitors on 
ethanol-induced sleep time. Finasteride had no effect on ethanol- induced 
LORR and did not alter cerebral cortical 3α,5α-THP levels at hypnotic 
ethanol doses in rats (Morrow et al., 2001b). Recently, Guidotti et al. 
showed that systemic administration of (17β)-17-[bis(1-
methylethyl)aminocarbonyl)]androsta-3,5-diene-3-carboxylic acid (SKF-
105,111) a 5α-reductase type-1 inhibitor to mice significantly reduced the 
duration of LORR induced by ethanol (Guidotti et al., 2001). In contrast, 
Atzori et al. presented evidence that SKF-105,111 did not modulate 
ethanol-induced LORR in mice (Atzori et al., 2001). In view of these 
conflicting reports, the present study systematically examined the effect of 
adrenalectomy and 5α-reductase inhibition on ethanol-induced increases in 
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3α,5α-THP levels and LORR in rats. Furthermore, the ability of 5α-DHP to 
reverse the effect of adrenalectomy on the effects of systemic ethanol 
administration was studied to determine the role of circulating steroids in 
ethanol-in- duced LORR. The results of this study clearly demonstrate that 
GABAergic neurosteroids contribute to the LORR induced by ethanol. 
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In Vitro Experiments. 
 
Materials. 
 
DMEM F-12, fetal bovine serum (FBS), cell culture media, and 
supplements were purchased from Cambrex Bio Science Verviers (B-800 
Verviers, Belgium). Protease and phosphatase inhibitors (leupeptin, trypsin 
inhibitor, phenylmethylsulfonylfluoride, Na3VO4), trypsin-EDTA solution, 
anti-β-actin antibody (clone AC-15) were purchased from SIGMA 
(SIGMA-Aldrich, St. Louis, MO, USA). 
GW6471 and PEA were purchased from Tocris Bioscience (Ellisville, 
Missouri). PEA was first dissolved in absolute ethanol and then diluted 
with DMEM. The final ethanol concentration was less than 0.5%. 
 
 
Cell cultures. 
 
The rat C6 cells, originating from a rat brain glioma, was a generous gift 
from Dr. Jan Cornelis, INSERM 375, Deutsches Krebsforschungszentrum, 
Heidelberg, Germany. 
C6 glioma cells were maintained in DMEM containing 10% FBS 
supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin at 
37°C in a humidified incubator under 5% CO2 and 95 % air. Cells were 
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passaged at confluence using a solution of 0.025% trypsin and 0.01% 
EDTA and used between passage 54-58. 
Primary astrocyte cultures were prepared from new-born BALB/c mice (up 
to 2 days old) by the method published by Marriot et al., 1995, and adapted 
from Burudi et al., 1999. 
The level of purity was confirmed by performing Western blot analysis on 
proteins from astrocytes lysates. Antibodies against the scavenger receptor 
(specific marker for microglia) and glial fibrillary acidic protein (specific 
marker for astrocytes) were used to detect the relative amount of 
contaminating microglia in astrocyte cell lysates. More than 95% pure 
astrocyte cultures were ensured. 
 
 
Cell treatments  and preparation of mitochondrial extracts. 
 
C6 glioma cells or astrocyte primary culture were incubated in serum-free 
DMEM at 37°C for at least 24 h before each experiment. Then, cells were 
treated with PEA (10µM), in the presence and absence of GW6471 (10µM) 
added 30 min prior to ethanolamide treatment. Then cells were incubated 
for 24 h in serum-free medium. Preparation of mitochondrial protein 
extracts from C6 or astrocytes was carried out as described by Hartl et al. 
(1986). 
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Western blot analysis. 
 
The protein concentration of the extracts were estimated by the Bio-Rad 
protein assay using bovine serum albumin as standard. Equal amounts of 
protein (20 or 40 µg) of nuclear and mitochondrial extracts were dissolved 
in Laemmli's sample buffer, boiled for 5 min, and subjected to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (8% polyacrylamide). 
Western blotting was performed by transferring proteins from slab gel to a 
sheet of nitrocellulose membrane at 240 mA for 40 min at room 
temperature. The filters were then blocked with 5% non fat dried milk in 
phosphate-buffered saline for 45 min at room temperature and incubated 
with the specific anti-StAR (1:500; Santa Cruz Biotechnology), or anti-
cytochrome P450scc (1:1,000; Chemicon), or anti-PPAR-α (1:500; Santa 
Cruz Biotechnology), antibody in 1X PBS, 5% non-fat dried milk and 0.1% 
Tween 20 (PMT) overnight at 4°C. Thereafter, the filters were incubated 
with the appropriate secondary antibody (anti-mouse or anti-rabbit IgG-
horseradish peroxidase conjugates, 1:2,000, Jackson Laboratories) for 1 h 
at room temperature. 
The antibody-reactive bands were revealed by chemiluminescence (ECL). 
To ascertain that blots were loaded with equal amounts of protein 
mitochondrial and nuclear lysates were analysed for the expression of 
hsp60 (Stressgene, 1:10,000) or lamin B1 protein (1:5,000; Sigma), 
respectively. The protein bands on X-ray film were scanned and 
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densitometrically analyzed by Model GS-700 Imaging Densitometer. 
 
 
Quantitative Analysis of Neurosteroids in C6 cell supernatant. 
 
Pregnenolone and allopregnanolone in C6 cell culture supernatants were 
first isolated by solid-phase extraction (SPE) on C18 columns (Varian) 
preconditioned with 2 ml methanol and 2 ml of  5% methanol in water. The 
loaded columns were eluted with 2 ml methanol. Eluates were dried under 
a nitrogen stream and then derivatized. For the evaluation of recovery, 
reproducibility and the generation of calibration curves, 500 µl of serum-
free DMEM medium used for C6 cell culture was used for each analysis. 
The response was linear in the range of 0.5 to 32 pg steroids in standard 
curve. Quantification of neurosteroid in samples is based on 
chromatographic peak areas of pregnenolone and allopregnanolone relative 
to their deuterated internal standards at 20pg. Derivatized samples and 
standard courve  were analysed by gas chromatography-mass spectrometry, 
according to the method of Vallée (2000) with slight modifications. Briefly, 
neurosteroids were reacted by adding 40µl pyridine and 20µl Florox at 5 
mg/ml to the evaporated C6 cell supernatant samples at 70°C for 45 min. 
The reaction mixture was evaporated off under a stream of nitrogen at 50°C 
and trimethylsilyl derivatives were formed by adding 15 µl of ethyl acetate 
and 15 µl of BSTFA  and reacted for 20 min at 70°C. 
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The derivatized samples were injected directly into a Shimadzu GCMS-
QP2010 (Shimadzu Corporation, Japan) via autosampler. The instrument 
was employed in negative ion chemical ionization (NICI) mode with 
methane as reactant gas (Air Products). A 15-m Rtx-5Sil MS (Restek, 
Bellefonte, PA) with a 0.25-mm inside diameter and 0.1-µm film thickness 
was employed for analyte resolution. Helium (ultra-high purity, Linde Gas) 
at linear velocity set at 60 cm/sec at 160°C was employed as carrier gas. 
Splitless injections of 1µl volumes were made at injector temperature of 
260°C. Splitless injection conditions were maintained for 0.5 min 
following sample injection. The capillary column temperature was 
maintained at 160°C for 1 min and the injector contents were split at a ratio 
of 25:1. One minute after sample injection, the column oven was heated to 
230°C at a rate of 60°C/min. The column oven temperature was 
subsequently raised to 260°C at a rate of 4°C/min and finally to 290°C at 
60°C/min. The transfer-line temperature was maintained at 290°C. 
Derivatized neurosteroids were first analyzed qualitatively by full scan in 
the mass range of 150-600. For quantification, the mass spectrometer was 
operated in the selected ion monitoring mode. 
Monitoring ions at m/z 411 and m/z 407 for allopregnanolone-
d4/allopregnanolone and m/z 566 and m/z 563 for pregnenolone-
d3/pregnenolone, respectively. The limit of quantification of GC/MS 
(LOQ) is defined as the signal equivalent to 10 times the noise (S/N of 
10:1). 
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siRNA Treatment. 
 
siRNA-mediated silencing of endogenous expression of PPAR-α in C6 
cells was performed using 21 nucleotide siRNA desalted duplexes 
(Eurogentec, Liege, Belgium). The sequence of sense and antisense 
oligonucleotides were 5 -GGGUGACAAGUUCAAGCUGtt-3  and 5 -
CAGCUUGAACUUGUCACCCtc-3 , respectively. PPAR-α siRNA was 
transfected with ICAFectin™ 442 according to the manufacturer's 
instructions (Invitrogen). Briefly, one day before transfection, C6 cells 
were resuspended in 12-well plates in appropriate growth medium and 
grown overnight. Then, the medium was changed to Opti-MEM 
(Invitrogen) 20 min before transfection. The siRNA complexes were added 
(20-80 pmol/L) while gently rocking the 12-well plates. Cells were 
transfected with PPAR-α siRNA for at least 4 h at 37°C before switching to 
fresh Opti-MEM containing 20% FCS, and subsequently incubated 
overnight. The medium was then changed to DMEM supplemented with 
3% glutamine, antibiotics (see above) and 10% FCS. As a control for 
PPAR- α, Silencer Negative Control #1 siRNA (Ambion) was also used. 
 
Statistics. 
 
Data are presented as mean ± SEM values of 3 independent determinations. 
All experiments were done at least three times, each time with three or 
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more independent observations. Statistical analysis was performed by one-
way ANOVA test and multiple comparisons were made by Bonferroni’s 
test. A value of P<0.05 was considered significant. 
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Results. 
 
 
PEA induces StAR activation and P450scc expression in 
mitochondrial fraction of C6 cells. 
 
Positioned at the cytosolic aspect of the outer mitochondrial membrane, 
StAR is functional and exhibit high activity, as 37-kDa preprotein. After 
its cleavage in mitochondrial membrane contact site, the 30 kDa “mature” 
StAR is produced to promote cholesterol transfer (Bose et al., 2002 a and 
b) from the outer to the inner membrane. The cleavage terminates the 
activity of the protein. Here, we showed that the stimulation of C6 cells 
with PEA leads to an increase of the mature form of StAR (fig. 11), an 
indirect rate of cholesterol transfer into the mitochondria. 
The reverting effect by a pre-incubation with GW6471, a PPAR-α 
antagonist, suggests the involvement of this receptor on PEA-induced 
StAR increase. No effect on StAR was observed when C6 cells were 
incubated with GW6471 alone. 
The net steroidogenic capacity is also determined by the expression of 
P450scc, which is the first and rate-limiting enzyme in steroidogenesis. 
PEA induces a significant increase in P450scc expression in the 
mithocondrial fraction of C6 cells and GW6471, which was unable itself, 
completely blunted PEA effect (fig. 12). 
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Fig. 11. Effect of PEA (10 µM) on StAR mature form expression in C6 cells pre-treated or not 
with GW6471 (10 µM). Treatment of cells was performed as described in Methods. 
Representative immunoblot is shown. The densitometric quantification of all determinations of 
three independent experiments is also reported. All data are expressed as mean ± SEM. Basal 
level of protein expression was also reported (CON). **p<0.01 vs CON; #P<0.05 vs PEA alone. 
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Fig. 12. Effect of PEA (10 µM) on CYP450scc expression in C6 cells pre-treated or not 
with GW6471 (10 µM). Treatment of cells was performed as described in Methods. 
Representative immunoblot is shown. The densitometric quantification of all 
determinations of three independent experiments is also reported. All data are expressed 
as mean ± SEM. Basal level of enzyme expression was also reported (CON). *P<0.05 
vs CON; ##P<0.01 vs PEA alone. 
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PEA failed in StAR and P450scc modulation in PPAR-α silenced C6 
cells. 
 
To further confirm the involvement of PPAR-α in PEA modulating effect of 
steroidogenic proteins StAR and P450scc, this receptor was silenced in C6 
cells. As depicted in fig. 13 A, Western blot showed that siRNA 
concentration-dependently inhibited the constitutive expression of PPAR-α, 
that was significantly reduced (~80%) at the highest concentration used (80 
pmol/L). Silencing negative control did not modify PPAR-α expression. 
In PPAR-αknock-down cells the increased amount of StAR and P450scc 
induced in control cells by PEA, was reduced about 70% and 77%, 
respectively (fig. 13 B and C). 
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Fig. 13. siRNA knock-down of PPAR-α in C6 cells (panel A). PEA-induced StAR activation 
(panel B) and CYP450scc expression (panel C) in cells silenced or not for PPAR-α 
expression. 
In panel A the constitutive PPAR-α expression was measured by Western blot analysis in 
lysates of C6 cells transfected with PPAR-α siRNA at increasing concentrations (20-80 
pmol/L). Silencer Negative Control (siRNA-N) was also analysed. Densitometric data are 
expressd as % of control untreated cells. ***P<0.001 vs untreated cells. 
Cells transfected or not with PPAR-α siRNA (80 pmol/L) were then stimulated with PEA 
(10µM) and StAR mature form (panel B) and CYP450scc (panel C) were analysed. 
Densitometric units of all determinations are reported. Data represent mean ± S.E.M. *P<0.05 
and **P<0.01 vs CON; ##P<0.01 and ###P<0.001 vs PEA. 
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PEA induces StAR and P450scc in mitochondrial fraction of primary 
murine astrocytes. 
 
PEA stimulation was also performed on murine primary astrocytes. As 
expected, PEA induced an increase of both proteins, StAR and P450scc, in 
the mitochondrial fraction of astrocytes and this effect was reverted by the 
pre-treatment with GW6471 (fig. 14 A and B). No significant modulation 
of both steroidogenic proteins was observed after GW6471 incubation 
alone. 
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Fig. 14. Effect of PEA (10 µM) on StAR (panel A) and CYP450scc (panel B) expression in 
primary murine astrocytes pre-treated or not with GW6471 (10 µM). Treatment of cells was 
performed as described in Methods. Representative immunoblots are shown. The densitometric 
quantification of all determinations of three independent experiments are also reported. All data 
are expressed as mean ± SEM. *P<0.05 vs CON; #P<0.05 and ##P<0.01 vs PEA. 
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PEA induces ALLO synthesis in C6 cell or primary astrocyte 
supernatant. 
 
Once inside the mitochondrion, cholesterol is the starting material for the 
synthesis of steroid hormones, oxysterols, and vitamin D, depending on 
cell type. Here, we measured the amount of ALLO synthesized after 24h 
PEA stimulation. While pregnenolone is the first metabolite of 
cholesterol, ALLO is synthesized from progesterone via two enzymatic 
reactions: 5α reduction of progesterone, yielding dihydroprogesterone, 
mediated by 5α reductase, followed by 3α reduction of the C3 ketone, 
mediated by 3α hydroxysteroid dehydrogenase. 
ALLO was significantly increased in the supernatant of PEA-stimulated 
glioma cells or primary astrocytes, and its synthesis was reverted by 
GW6471 pre-treatment (fig. 15 A and B). No significant effect was induced 
by GW6471 alone. 
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Fig. 15. Effect of PEA (10 µM) on ALLO production evaluated in the supernatant of C6 cells 
(panel A) or primary murine astrocytes (panel B) pre-treated or not with GW6471(10 µM). 
Treatment of cells was performed as described in Methods. All data expressed in pg/ml are 
mean ± SEM of three independent experiments. *P<0.05 and ***P<0.001 vs CON; ##P<0.01 
and ###P<0.001 vs PEA. 
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In Vivo Experiments. 
 
Materials and methods. 
 
 
Animals. 
 
Male Swiss mice weighing 20 to 25 g were purchasedfrom Harlan (Udine, 
Italy). They were housed in stainless steelcages in a room kept at 22 ± 1°C 
on a 12/12-h light/darkcycle. The animals were acclimated to their 
environment for1 week, and they had ad libitumaccess to tap water and 
standardrodent chow. 
Mice (4–5weeks old; 20–22 g) with a targeted disruption of thePPAR-α 
gene (PPAR-α knockout) and their wild-type littermate controls (PPAR-α 
wild type) were purchased from Jackson Laboratories (HarlanNossan, 
Italy). Mice homozygous for the PparatniJGonz-targetedmutation are viable, 
fertile, and they seem normal in appearanceand behaviour (Genovese et al., 
2005). Animal care was in compliancewith Italian regulations on protection 
of animals used for experimentaland other scientific purposes (D.M. 
116192) as well as with European Economic Community regulations (O.J. 
of E.C. L 358/112/18/1986). 
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Materials and treatments. 
 
Pentobarbital sodium was purchased from Carlo Sessa S.p.A. (Italy), 
palmitoylethanolamide (PEA), GW7647, GW0742 and ciglitazone were 
purchased from Tocris Cookson Ltd. (UK); aminoglutethimide (AMG), 3α-
hydroxy-5α-pregnan-20-one (allopregnanolone, ALLO), charybdotoxin and 
iberiotoxin were purchased from Sigma-Aldrich (Italy); finasteride (FIN) 
was procured from Steraloids (Newport, RI); Rimonabant, CB1 antagonist, 
was a generous gift from Sanofi (France). For quantitative analysis of 
allopregnanolone, deuterium-labeled standards (≥ 98% chemical purity) 
3α-hydroxy-5α-pregnan-20-one-d4 (allopregnanolone-d4) was a gift from 
Dr. Purdy (The Scripps Research Institute, La Jolla, USA). Derivatizing 
agents including pyridine, O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine 
hydrochloride (Florox) and N,O-bis(trimethylsilyl)trifluoroacetamide with 
1% Trimethylchlorosilane (BSTFA+TMCS) were purchased from Sigma-
Aldrich, (Italy). 
Pentobarbital (20 mg/kg) was dissolved in saline and injected into the 
caudal vein (i.v.). Just before pentobarbital injection, PEA, GW7647, 
GW0742, ciglitazone, rimonabant, FIN and AMG or vehicle were 
dissolved in apirogen and distilled water with PEG (10%)/Tween 80 (5%). 
Charybdotoxin and iberiotoxin were dissolved in distilled water. Drugs 
were injected intracerebroventriculary (i.c.v.) in a constant volume of 2µl 
per mouse, using a 25-µl glass Hamilton which needle was modified with a 
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shaft, so to control injection depth at 2 mm, according to the method of 
Haley and McCormick (1957) (2mm lateral, 2mm caudal to bregma and 2 
mm deep). 
 
 
Measurement of pentobarbital-induced LORR. 
 
In order to evaluate the potentiation effect of hypnosis induced by 
pentobarbital, mice were randomly divided into groups of 10 animals and 
each group was i.c.v. injected with drugs tested just before the sodium 
pentobarbital (20 mg/kg) administration into the tail vein. The control 
group animals were i.c.v. injected with 2µl of vehicle. LORR time was 
defined as the loss of righting reflex, while time to recovery of this reflex 
determined the hypnosis endpoint. The time from the loss of righting reflex 
to spontaneous recovery was considered as the LORR duration (Matsumoto 
et al., 1991). 
 
 
Electroencephalographic recording (EEG). 
 
Mice were chronically implanted with five electrodes for EEG recordings 
and a guide cannula for i.c.v. administration under chloral hydrate 
anaesthesia (40 mg/kg i.p.; Carlo Erba, Milan, Italy), using a Kopf 
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stereotaxic instrument (according to the brain atlas of Paxinos and Franklin, 
2001). 
Electrode leads were soldered to a miniature connector, which was head-
mounted with cranioplastic cement and mounting screws. After surgery, 
animals were allowed to recover for at least one week before EEG 
recording. To habituate animals to the recording conditions, mice were 
connected to the recording cables for at least 3 days before the experiments. 
Animals were attached to a multichannel amplifier (Astro-Med, West 
Warwich, USA) by a flexible recording cable and an electric swivel, fixed 
above the cages, permitting free movements of the animals. 
Mice were randomly divided into groups of 6-8 animals. Two 
groupsreceived PEA (1 or 3µg/2µl i.c.v.), while the control group was i.c.v. 
injected with 2µl of vehicle, than, 30 min after, all groups received the i.p. 
injection of pentobarbital (40 mg/kg). 
Every recording session lasted from a minimum of 2 to a maximum of 5 
hours: 1h baseline without injection, and after LORR induction the 
recordings always lasted up to 1 hour following awakening; in the groups 
pre-treated with PEA 30 extra minutes were recorded after baseline 
recordings and before pentobarbital. 
EEG was high-pass filtered with a 0.5-Hz half-amplitude filter (6 
dB/octave) and low-pass filtered with a 35-Hz half-amplitude filter (12 
dB/octave). EEG channels were analog-to-digital converted to a 
samplingrate of 200 Hz. 
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Rotarod test. 
 
To evaluate motor neurological deficits of mice, we used the rotarod test, 
which measures balance, coordination and motor control. The rotarod 
apparatus (Ugo Basile, Comerio, Italy) consists of a suspended rod able to 
run at constant or accelerating speed. All mice were exposed to a 5-min 
training period, at constant speed (4.5 rpm), immediately before the test to 
familiarize them with the apparatus. Treated mice were randomly divided 
into three groups of 6 animals and each group was i.c.v. injected only with 
PEA (1, 3 and 5 µg/2 µl). Control group were i.c.v. injected with 2µl of 
vehicle. During the test the mice had to remain on the rod for as long as 
they could. The length of time that the animal remained on the rod was 
recorded (a 60 s maximal trial was used for the test) 30 and 60 min after 
administration of PEA. 
 
 
Preparation of total tissue protein extracts from brainstem. 
 
In another set of experiments, brainstem obtained from 3 animals at 
different time points (15min. And 30min. after PEA and 
pentobarbitaladministration), were homogenized on ice in lysis buffer (10 
mM Tris-HCl, 20 mM pH 7.5, 10 mM NaF, 150 mM NaCl, 1% Nonidet P-
40, 1 mM phenylmethylsulphonyl fluoride, 1 mM Na3VO4, leupeptin and 
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trypsin inhibitor 10 µg/ml; 0.25 ml per 50 mg tissue). After 1 h, tissue 
lysates were centrifuged at 100,000xg for 15 min at 4°C, and supernatant 
was stored at -80° until use. All the extraction procedures were performed 
on ice using ice-cold reagents. 
 
 
Western blot analysis. 
 
Protein content was measured using bovine serum albumin (Sigma Aldrich) 
as a standard. Total extract (for StAR and P450scc) containing equal 
amount of protein were separated on sodium dodecyl sulfate-
polyacrylamide minigels and transferred onto nitrocellulose membranes 
(Protran Nitrocellulose Transfer Membrane Schleicher & Schuell 
Bioscience, Dassel, Germany), blocked with phosphate-buffered saline 
(PBS) containing 5% non-fat dried milk for 45 min at room temperature, 
and incubated at 4°C, overnight in the presence of commercial antibodies 
for StAR (Santa Cruz Biotechnology; dilution 1:500); or P450scc 
(Chemicon International Antibodies; dilution 1:500) in PBS containing 5% 
non-fat dried milk, 0.1% Tween 20. The secondary antibody (anti-mouse 
IgG, or anti-rabbit IgG, or anti-goat peroxidase conjugate) was incubated 
for 1 h at room temperature. Blots were washed with PBS, developed using 
enhanced chemiluminescence detection reagents (Amersham Pharmacia, 
Piscataway, NJ) following manufacturer’s instructions, and exposed to X-
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Omat film (Eastman Kodak Co., Rochester, NY). Protein bands for StAR 
(~30 kDa) and P450scc (~50 kDa), were quantified using a model GS-700 
imaging densitometer (Bio-Rad Laboratories). alpha-tubulin protein 
(dilution 1:1000; Sigma-Aldrich, Milan, Italy) was performed to ensure 
equal sample loading. 
 
 
Quantitative Analysis of Neurosteroids. 
 
ALLO in brainstem samples was isolated by solid-phase extraction (SPE). 
Briefly, 10 to 50 mg of tissue samples were spiked with 20 pg of 
deuterium-labelled standards and applied onto 100 mg C18 columns 
(Varian C18 cartridges) preconditioned with 2 ml methanol and 2 ml of 5% 
methanol in water. The loaded columns were washed with 2 ml of 5% 
methanol in water followed by 2 ml of 50% methanol in water. ALLO was 
eluted with 2 ml methanol into 5 ml glass vials. The methanol eluate was 
dried under a nitrogen stream prior to derivatization. For the evaluation of 
recovery, reproducibility and the generation of calibration curves, 200 µl of 
a brainstem (20 mg of tissue) was used for each analysis. The pool 
containing increasing known quantities of ALLO standard ranging from 0.5 
to 32 pg was spiked with 20 pg of deuterated standard and SPE extraction 
procedure was performed as described above. The response was linear in 
the range of 0.5 to 32 pg, standard curve generated with 20 pg of internal 
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standard was interpolated for quantization of neurosteroid in samples. 
Dried methanol extracts of biological samples and standards were 
derivatized for capillary gas chromatography-mass spectrometric analysis 
according to the method of Vallée (2000) with slight modifications. Briefly, 
neurosteroids were reacted by adding 40µl pyridine and 20µl Florox at 
5mg/ml to the evaporated brain and spinal cord samples at 70°C for 45 
min. The reaction mixture was evaporated off under a stream of nitrogen at 
50°C and trimethylsilyl derivatives were formed by adding 15µl of ethyl 
acetate and 15 µl of BSTFA  and reacted for 20min at 70°C. 
The derivatized saples were injected directly into a Shimadzu GCMS-
QP2010 (Shimadzu Corporation, Japan) via autosampler. The instrument 
was employed in negative ion chemical ionization (NICI) mode. The ion 
source temperature was mantained at 200°C, and the ion source pressure 
was maintained at 0.7-0.8 Torr with CH4 as reactant gas methane (research 
grade 5.0, 99.9995% Air Products). The emission current was 60µA, and 
the electron energy set at 70eV. A 15-m Rtx-5Sil MS W/Integra Guard 
capillary columns (Restek, Bellefonte, PA) with a 0.25-mm inside diameter 
and 0.1-µm film thickness was employed for analyte resolution. Helium 
(ultra-high purity, Linde Gas) at linear velocity set at 60 cm/sec at 160°C 
was employed as carrier gas. Splitless injections of 1µl volumes were made 
at injector temperature of 260°C. Splitless injection conditions were 
maintained for 0.5 min following sample injection. The capillary column 
temperature was maintained at 160°C for 1 min and the injector contents 
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were split at a ratio of 25:1. One minute after sample injection, the column 
oven was heated to 230°C at a rate of 60°C/min. The column oven 
temperature was subsequently raised to 260°C at a rate of 4°C/min and 
finally to 290°C at 60°C/min. The transfer-line temperature was maintained 
at 290°C. Derivatized neurosteroids were first analyzed qualitatively by full 
scan in the mass range of 150-600. For quantification, the mass 
spectrometer was operated in the selected ion monitoring mode. 
The limit of quantification of GC/MS (LOQ) is defined as the signal 
equivalent to 10 times the noise (S/N of 10:1). However, the 10:1 S/N 
definition of LOQ does not address accuracy. We then, include accuracy in 
the LOQ by measuring the lowest  amount of neurosteroid by GC/MS with 
a minimum error of +/- 20% in triplicate standard samples (Vallée, et al 
2000). 
 
 
Statistical Analysis 
 
Data experiments were analyzed with t-test or one-way analysis of variance 
(ANOVA) followed by Dunnett’s test. The significance of differences 
among groups was determined by two-way analyses of variance (ANOVA) 
followed by Bonferroni post hoc test for multiple comparisons. 
The EEG signals were amplified and converted into digital values using a 
(FFT); spectral powers were then digitally calculated in real time and their 
  78 
densities integrated and averaged every 30 min (60 epochs). From FTT 
Discrete Fourier Transform (DFT) was efficiently and rapidly calculated 
for analysis of dominant frequency. Quantitative changes in EEG power for 
each of 4 frequency bands, [δ (0.5-4 Hz), θ (4-8 Hz), α (8-13 Hz) and β 
(13-18Hz)] were analyzed in the power spectrum of each 30 min from mice 
administrated with various treatment with respect to the their control period 
(Deboer et al., 2007). To quantify the changes induced by pentobarbital, or 
its combination with PEA, of total voltage power and preselected bands of 
frequency, the values obtained as V2/sby FFT, during periods of 30 min, 
were converted as percentage of change in comparison to the same interval 
referred to the baseline period. In addition, to reduce possible inter-animal 
variations of the baseline electrocortical activity and single frequency 
bands in the same group, the percentage changes after treatment with drugs 
were compared to the values for the corresponding period before treatment, 
using paired Student’s t-test. (De Sarro et al., 1990; 1995; 2000). 
Difference with P<0.05 was considered statistically significant. 
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Results. 
 
 
Effects of PPAR-α agonists on pentobarbital-induced LORR. 
 
In order to evaluate the effect of endogenous PPAR-α agonists (PEA) and 
synthetic (GW7647) on hypnosis induced by pentobarbital LORR time was 
determined. Both agonists increase LORR time in a dose-dependent 
manner. In fact, this effect was significant in a range of 2-5 µg/mouse 
(p<0.01; fig. 16 A and B), in particular at 3 µg/mouse, the LORR duration 
was two fold increased respect to vehicle. Thus to determine the selective 
involvement of PPAR-α in the increase of LORR duration, we used 
ciglitazone, a PPAR-γ agonist, and GW0742, a PPAR-δ agonist, even at 
higher doses than those used for PPAR-α agonists. Both drugs at all doses 
tested (1-10 µg/2 µl/mouse), did not shown effect on pentobarbital-induced 
LORR (fig. 16 C and D), indicating the pivotal role of PPAR-α receptors. 
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Fig. 16. Effect of PPAR agonists on pentobarbital-induced LORR: PEA (PPAR-α endogenous  
agonist, 1-5 µg/2µl, panel A), GW7647 (PPAR-α synthetic agonist, 1-5 µg/2µl, panel B), 
ciglitazone (PPAR-γ agonist, 1-10 µg/2µl, panel C) and GW0742 (PPAR-β/δ agonist,1-10 
µg/2µl, panel D) were i.c.v. injected just before pentobarbital administration (20 mg/kg, iv). 
After injecting pentobarbital, LORR time was measured in mice (n=6, each group) and 
expressed as mean ± SEM. 
Control animals received i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water); *** p<0.001 
versus vehicle. 
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To confirm the involvement of PPAR-α receptor in PEA and GW7647 
modification of the hypnotic effect of pentobarbital, we tested the most 
active dose of PEA and GW7647 (3 µg) on wild-type (+/+) and PPAR-α 
knockout (-/-) mice (fig. 17). No differences in LORR time induced by 
pentobarbital was evidenced between wild-type and knockout mice, 
however the increased LORR time induced by PPAR-α agonists (PEA and 
GW7647) was evidenced only in wild-type mice (fig 17 A and B), whereas 
disappeared in knockout mice (fig 17 C and D). 
Meanwhile, also other nuclear receptors belonging to the class of PPAR 
have been reported in CNS, we decided to determine if PPAR-γ and PPAR-
δ agonist could increase pentobarbital-induced LORR time, as endogenous 
PPAR-α agonist PEA does. 
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Fig. 17. Effects of PPAR-α agonists (PEA and GW7647) on pentobarbital-induced LORR time 
in wild-type (+/+) and PPAR-αknockout (-/-) mice. PEA (3 µg/2µl) or GW 7647 (3 µg/2µl) were 
i.c.v. injected just before pentobarbital administration in wild-type (+/+) (panel A and B, 
respectively) or PPAR-α (-/-) (panel C and D, respectively) mice. After injecting pentobarbital, 
LORR time was measured in mice (n=6, each group) and expressed as mean ± SEM. Control 
animals received i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water); **p<0.01 versus 
vehicle. 
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Involvement of cannabinoid system in PEA-induced effect on 
pentobarbital-induced LORR. 
 
Several possible scenarios have been proposed to describe the mechanism 
of action of PEA and one of this is the indirect action on cannabinoid 
system. To elucidate the involvment of CB1 receptor we used Rimonabant, 
a CB1 antagonist. Fig. 18 reports the Rimonabant (i.p.; 1 mg/kg, 30 min 
before pentobarbital injection) effect on PEA increase pentobarbital-
induced LORR time. Rimonabant  alone did not modify this parameter and  
and in combination with PEA did revert its effect. 
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Fig. 18. Effect of CB1 antagonist on PEA-increased LORR time induced by pentobarbital. 
Rimonabant, a CB1 antagonist, alone (1 mg/kg) or in combination with PEA (3 µg) was  i.p. 
Injected 30 min. before pentobarbital administration. After injecting pentobarbital, LORR time 
was measured in mice (n=6, each group) and expressed as mean ± SEM. Control animals (open 
bars) received i.c.v. vehicle just before pentobarbital administration (10% PEG, 5% Tween 80 in 
distilled water); *** p<0.001 and °°° p <0.001 versus vehicle. 
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Effects of PEA on behavioural and EEG LORR induced by 
pentobarbital. 
 
To exclude that PEA per se could induce motor neurological deficits, PEA 
(1 and 3µg/2µl) was given i.c.v. in mice (n=6-8 mice for each group). The 
treatment did not produce any noticeable change in locomotor activity and 
EEG parameters during an observation time of 150 min. 
Pentobarbital (40 mg/kg), injected i.p. induced behavioral and EEG signs 
with a mean latency of 167 ± 24 sec; the LORR state lasted for an average 
of 55±6 min (n=6), considered as complete immobility of the animal 
accompanied by a typical slow wave activity on the EEG. FFT analysis of 
EEG recordings revealed a significant time-dependent modifications in 
total voltage power (10-20%), as well as in the 0.5-4 Hz band (delta ~10%), 
a small no significant increase in the 13-18 (beta ~5%) and a significant 
decrease in the 8-13 (alpha ~10%) Hz frequency bands. No significant 
changes in the 4-8 Hz (theta) frequency band were observed (fig. 19). 
Pretreatment with PEA (i.c.v.; 1 or 3µg/2µl, 30 min before pentobarbital 
administration) in mice, enhanced the behavioral and EEG effects induced 
by pentobarbital (40 mg/kg, i.p.). 
The LORR state was significantly prolonged to 69.6±6 min after the 
combined treatment with PEA (1µg/2µl) and 115±10 min after PEA 
(3µg/2µl). During the combined treatment, EEG recordings were 
characterized by an evident increase in slow wave activity; FFT analysis 
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revealed a significant increase in total voltage power in comparison to 
control animals. It was more pronounced and significantly different (~25% 
PEA 1µg/2µl; ~35% PEA 3µg/2µl) when compared to vehicle (10-20%) 
administration. 
A statistical comparison between combined treatment and pentobarbital 
alone revealed a significant dose-dependent increase of delta (0.5-4Hz; Fig 
19 A), beta (13-18Hz; Fig. 14 D) band and a significantly lowering of theta 
and alpha total power (fig. 19 B and C, respectively) for PEA pre-treated 
animals, at both doses. 
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Fig. 19. Elettroencephalografic effect of PEA (1 and 3 µg/2µl) on pentobarbital induced LORR. 
PEA was i.c.v. injected 30 min. before pentobarbital administration (40 mg/kg, ip.). Control 
animals received i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water). Modifications of 
alpha, beta, delta and theta frequency bands were reportedas % of total variations of total power; 
* p<0.05 and ** p<0.01versus vehicle. 
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Effects of PEA on performance in the rotaroad test. 
 
To evaluate the possible muscle relaxant or sedative activity of PEA, we 
used a the rotaroad test. PEA showed no reduction in the permanence (time 
in seconds) of the mice on the apparatus 30 min. and 60 min. after the 
administration of all doses used (Table 1), suggesting the absence of 
sedative effects. 
 
 
TREATMENT n 30 min. 60 min. 
Vehicle 10 56.10 ± 4.70 55.80 ± 5.00 
PEA 1 µg 10 55.30 ± 5.41 54.80 ± 4.54 
PEA 3 µg 10 56.80 ± 5.36 55.70 ± 5.42 
PEA 5 µg 10 57.00 ± 6.30 59.90 ± 4.73 
 
 
Table 1: Effect of PEA (1-5 µg/ 2µl/ mouse) on rotarod test. The length of 
time that the animal remained on the rod was recorded 30 and 60 min after 
administration of PEAand expressed as mean ± SEM. Control animals 
received i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water). 
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Involvement of neurosteroids in PEA-induced effect on pentobarbital-
induced LORR. 
 
To explore the role of neurosteroids on the increased LORR time induced 
by pentobarbital, we used the inhibitors of two key enzymes of 
neurosteroidogenesis, AMG and FIN. 
AMG, an inhibitor of P450scc, blocks the conversion of cholesterol to 
pregnanolone, the first biosynthetic step of neurosteroid cascade. FIN, is an 
inhibitor of 5α reductase, a key enzyme for the 5α reduced neurosteroid 
production, such as ALLO. Both inhibitors caused a significant 
dose/response reduction of pentobarbital-induced LORR time at the dose of 
3-10 µg/2µl i.c.v. (fig. 20). For this reason we chose the dose of 1 µg/2µl, 
that it was ineffective per se on pentobarbital-induced LORR time by itself, 
in order to verify the involvement of steroidogenic pathway on PEA-
induced increase of LORR time. Fig. 21 A and B reports the AMG and FIN 
effects on PEA increase pentobarbital-induced LORR time, respectively. 
AMG and FIN alone did not modify this parameter, while they significantly 
reverted PEA effect (p<0.01). 
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Fig. 20. Effect of AMG (P450scc inhibitor, 1-10 µg/ 2µl/ mouse) and FIN (5-α reductase 
inhibitor, 1-10 µg/ 2µl/ mouse) on pentobarbital.induced LORR time. AMG and FIN were i.c.v. 
injected just before pentobarbital administration. After pentobarbital injection, LORR time was 
measured in mice (n=6, each groups) and expressed as mean ± SEM. Control animals received 
i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water) just before pentobarbital 
administration; * p<0.05, ** p<0.01, *** p<0.001 versus vehicle. 
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Fig. 21. Effect of neurosteroidogenic enzyme inhibitors on PEA-increased LORR time induced 
by pentobarbital. Panel A: aminoglutethimide, a P450scc inhibitor, alone (AMG, 1 µg) or in 
combination with PEA (3 µg) was i.c.v. injected just before pentobarbital administration. Panel 
B: finasteride, a 5-α reductase inhibitor, alone (FIN, 1 µg) or in combination with PEA (3 µg) 
was injected just before pentobarbital administration. After injecting pentobarbital, LORR time 
was measured in mice (n=6, each group) and expressed as mean ± SEM. Control animals (open 
bars) received i.c.v. vehicle just before pentobarbital administration (10% PEG, 5% Tween 80 in 
distilled water); *** p<0.001 versus vehicle, and ### p <0.001 versus PEA. 
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PEA increases ALLO concentration in the brainstem. 
 
To further investigate if the increase of PEA on pentobarbital-induced 
LORR involves neurosteroid synthesis, we evaluated the concentration of 
neurosteroids in the brainstem. Among neurosteroids that might be 
modulated by PEA, we focused our attention on ALLO, because it is well 
known to be the most important neurosteroid related to LORR, acting as an 
allosteric modulator of GABAA receptor. 
We evaluated the ALLO content in this tissue after pentobarbital injection 
alone or in combination with PEA. PEA (3 µg) significantly increased 
ALLO concentration (p<0.01) both at 15 and 30 minutes after pentobarbital 
treatment (fig. 22). We chose these point times to compare the ALLO 
content between vehicle and PEA treated groups. In particular, the second 
time point (30 minutes) was chosen as last time in which pentobarbital was 
still active, just before the recovering of righting reflex. Interestingly, a 
trend increase of ALLO was seen in tissue obtained from animals treated 
with pentobarbital alone, both at 15 and 30 minutes. 
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Fig. 22. Brainstem ALLO levels, expressed as ng/g of tissue, were obtained from untreated 
(naïve, open bar), PEA (3 µg, i.c.v.) and /or pentobarbital treated animals. Brainstems were 
collected 15 and 30 min after pentobarbital injection or PEA treatment. All data are expressed as 
mean ± SEM; ** p<0.01 versus pentobarbital alone. 
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Effect of allopregnanolone alone or in combination with PEA on 
pentobarbital-induced LORR. 
 
The ability of neurosteroids to increase pentobarbital-induced LORR time 
was determined using exogenous ALLO (1-30 µg, i.c.v.), the principal 5 α–
reduced neurosteroid able to modulate GABAA receptor. At the highest 
dose used, ALLO significantly prolonged (p<0.01) the duration of 
pentobarbital-induced LORR time (fig. 23 A). 
Interestingly, when the inactive doses of ALLO and PEA (1 µg each) were 
co-injected, an evident synergistic effect was shown, inducing a two-fold 
increase (p<0.01) of pentobarbital-induced LORR duration (fig. 23 B). 
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Fig. 23. Effect of ALLO on pentobarbital-induced LORR time: ALLO (1-30 µg/2µl, panel A), 
positive allosteric modulator of GABAA receptor, was i.c.v. injected just before pentobarbital 
administration (20 mg/kg, i.v.). PEA (1 µg/1µl) and ALLO (1 µg/1µl) (panel B) were 
coadministrated just before pentobarbital injection. LORR time duration was measured in mice 
(n=6, each group) and expressed as mean ± SEM. Control animals received i.c.v. vehicle (10% 
PEG, 5% Tween 80 in distilled water) just before pentobarbital administration; ** p<0.01 and 
*** p<0.001 versus vehicle. 
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Effect of Calcium-Activated K+ Channels (KCa) on PEA increasing 
pentobarbital-induced LORR time. 
 
To exclude the involvement of KCa channels in PEA increasing 
pentobarbital-induce LORR time, we used charybdotoxin (1µg/2µl), an 
inhibitor of large-conductance KCa channels (BKca, KCa1.1) and 
intermediate-conductance KCa channels (IKCa, KCa3.1) and the selective 
BKca inhibitor iberiotoxin (1µg/2µl). The administration of two blockers 
did not modify the effect of PEA, indicating that IKca and BKca channels 
are not involved (Fig. 24). 
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Fig. 24. Effect of Calcium-Activated K+Channels blockers on PEA increasing pentobarbital-
induced LORR time. Charybdotoxin, an inhibitor of BKca and IKca, and the selective BKca 
inhibitor iberiotoxin, alone (1 µg/ 2 µl/ mouse) or in combination with PEA (3 µg) were i.c.v. 
injected just before pentobarbital administration. After pentobarbital injection, LORR time was 
measured in mice (n=6, each groups) and expressed as mean ± SEM. Control animals received 
i.c.v. vehicle (10% PEG, 5% Tween 80 in distilled water) just before pentobarbital 
administration; *** p<0.001 versus vehicle. 
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Effect of PEA and GW7647 on StAR and P450scc expression in the 
brainstem. 
 
To further confirm the involvement of de novo-neurosteroid synthesis in 
PEA-induced LORR time increase, we evaluated the brainstem-expression 
of StAR and P450scc, two enzymes that have been implicated in the early 
step of neurosteroidogenesis. When the animals were treated with 
pentobarbital and immediately euthanized, no significant difference in 
basal expression of either enzyme was seen (fig. 25). On the other hand, 
Western blot analysis revealed an increase of StAR and CYP450scc 30 
minutes after co-administration of PEA (3 µg) and pentobarbital (fig. 25 A). 
Densitometric analysis of all determinations at 15 and 30 minutes was also 
reported, confirming the augment of both proteins (fig. 25 B and C). 
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Fig. 25. Expression of StAR and P450scc in the brainstem of animals treated with PEA(3 
µg/2µl) and/or pentobarbital. The effect was evaluated 15 and 30 min after pentobarbital or drug 
injection. A representative immunoblot (panel A) is shown. The densitometric quantification of 
all determinations (n=6 mice) of StAR and P450scc expression at 15 and 30 min. are also 
reported (panels B and C): All data are expressed as mean ± SEM. Basal level of enzyme 
expression was also reported (lane 1). Equal loading was confirmed by alpha-tubulin staining. 
**p<0.01 versus basal level; ##p<0.01 versus PEA alone. 
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Discussion. 
 
Palmitoylethanolamide (PEA), a member of the fatty-acid ethanolamide 
family, acts as an endogenous PPAR-α ligand exerting analgesic and anti-
inflammatory effects (Calignano et al., 2001, Lo Verme et al., 2005 and 
2006; D’Agostino et al., 2007). Although the presence of PEA (Cadas et al., 
1997; Petrosino et al., 2007) and the discovery of PPAR-α receptors in the 
CNS (Kainu et al., 1994; Moreno et al., 2004) has been reported, their role 
in these areas remain to be elucidate. 
The present study provides evidence that PPAR-α receptor and its putative 
endogenous ligand, PEA, could regulate neurosteroidogenesis. 
After in vitro experiments, we report that the incubation of astrocytes with 
PEA, at higher concentration than physiological levels, enhances the 
expression of P450scc the first and main steroidogenic enzyme involved in 
de novo synthesis of neurosteroids, which converts cholesterol to 
pregnenolone, the precursor of neuroactive hormones. The rate of 
cholesterol transport from intracellular stores to the inner mitochondrial 
membrane is another limiting step in pregnenolone formation and involves 
both PBR and StAR both in peripheral and central tissues (Hauet et al., 
2002; Karri et al., 2007). 
Differently from steroidogenic enzymes, which have long half-lives and 
are chronically regulated, StAR protein is not an enzyme, is acutely 
regulated and its active form is highly labile and must be continuously 
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synthesized. Several differences were noted between StAR expression and 
steroidogenesis in astrocytes and other steroid-producing cells. One 
important difference is that astrocytes in cell culture have significant level 
of StAR expression in absence of stimulation (Karri et al., 2007). This 
basal level of StAR can be upregulated by hormone stimulation but this 
process occurs over a range of hours, and not minutes, such as in various 
endocrine cells (Stocco, 2001 a). In our experimental conditions, the 
capability of PEA to modulate cholesterol metabolism not only implies 
the modulation of P450scc, but also StAR protein activation, increasing 
both mitochondrial cholesterol availability and its subsequent conversion 
into pregnenolone. PEA effects on StAR and P450scc are accompanied by 
a strong increase of ALLO, one of the metabolites of the neuroactive 
steroid progesterone. Neuroendocrinological studies have demonstrated 
that a variety of vital neuronal and glial functions are influenced by the 
autocrine/paracrine actions of locally produced neurosteroids. After brain 
injury, progesterone and its metabolites can exert protective effects on 
neurons and glial cells by preventing cerebral edema, necrosis, apoptosis, 
and inflammation, while enhancing neuroregenerative mechanisms (De 
Nicola, 1993; He et al., 2004; Djebaili et al., 2004; Shear et al., 2002). In 
particular, ALLO’s neuroprotective and antineurodegenerative effects 
affect neurogenesis (Brinton and Wang, 2006), and inhibit toxin-induced 
cell death (Waters et al., 1997). Recently, ALLO was identified as a 
regenerative factor to promote functional neurogenesis and diminish 
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Alzheimer's pathology (Wang et al., 2008). 
Here, we show that PEA stimulation induces a significant increase in 
ALLO concentration in C6 and primary astrocyte medium, as 
quantitatively revealed by gas chromatography-mass spectrometry 
analysis. The appreciable level of StAR in untreated cells suggest that this 
protein has a basal physiological activity in astrocytes, according with 
previous findings of Karri et al. (2007). We also observed that these cells 
required a long time period (24 hr) to induce a detectable release of 
ALLO from untreated or PEA-stimulated astrocytes, suggesting that the 
regulation of neurosteroid synthesis in astrocytes is mediated by StAR, 
but with a slower time course of action, as it occurs in endocrine cells. 
About the molecular mechanisms underlining several PEA effects, they 
have been related to several cell surface and intracellular receptors. PEA 
exhibits poor affinity for cannabinoid CB1 or CB2 receptors (Lambert et 
al., 1999) and exerts per se only a negligible effect on vanilloid type-1 
receptor even at high concentrations (Zygmunt et al., 1999; Smart et al., 
2000), its effects have been proposed to involve indirect activation of 
these receptors, either through inhibition of AEA hydrolysis, or indirectly 
increasing 2-AG production (Lo Verme et al., 2005). However, the anti 
inflammatory effects of PEA involve nuclear PPAR-α which leads to the 
transcription of target genes upon ligand activation. PEA activates this 
receptor in cell based assays and its transcriptional activity, causing anti-
inflammatory, in both 12-O-tetradecanoylphorbol-13-acetate-induced and 
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carrageenan-induced oedema, blunted in PPAR-αknockout mice (Lo 
Verme et al., 2005; D’Agostino et al., 2007). 
The role of PPAR-α receptor on PEA induced neurosteroids synthesis is 
supported by our experimental evidence: the synthetic PPAR-α antagonist, 
GW6471, reverted the effects of PEA (i.e. StAR activation, P450scc 
expression and ALLO production) and most importantly, knock-down of 
PPAR-α in C6 cells completely blunted PEA-induced increase of StAR 
mature form and P450scc expression. 
Our data support a physiological role and pharmacological properties of 
PEA in CNS, where PEA is found in significant levels in whole mouse or 
rat brains and could play homeostatic and protective role, also trough 
neurosteroids, both in physiological and pathological conditions, when its 
concentration strongly increases. In fact, PEA concentration dramatically 
increased as a result of diverse neuropathological conditions (Franklin et 
al., 2003), and a protective role of PEA in neuroinflammation or after 
transient focal cerebral ischemia was strongly reinforced (Lambert et al., 
2002 a; Schomacher et al., 2008). 
According with previous data (Watanabe et al., 1999), with in vivo 
experiments we demonstrate that PEA significantly and in a dose-
dependent manner increases pentobarbital-induced LORR duration. It is 
worthy of note that PEA did not cause a sedative or hypnotic effect by itself 
after i.c.v. injection. Thus, PEA did not cause but was able to modulate 
molecular mechanisms involved in pentobarbital-induced effect. 
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The pivotal role of PPAR-α activation in PEA effect was strongly supported 
by the evidence that it was absent in PPAR-α-/- mice and mimicked by the 
synthetic PPAR-α agonist GW7647. Moreover, synthetic agonists of PPAR-
γ and PPAR-δ, ciglitazone and GW0742 respectively, did not modulate 
pentobarbital-induced LORR duration. 
These results show the key role of PPAR-α for this central effect of PEA, 
strengthening our previous observation about the involvement of this 
receptor in anti-inflammatory and analgesic effect of PEA (Calignano et al., 
2001, Lo Verme et al., 2005 and 2006; D’Agostino et al., 2007 and 2009). 
Our results also indicate that PEA may be involved in the alteration of EEG 
spectra inducing a higher delta and lower theta range during LORR. 
Pentobarbital-induced hypnotic effects involve more pronounced 
depression of the central nervous system than mere sedation. We show that 
these effects include shortening of LORR latency, increase of total LORR 
time and efficiency, and enhancement of EEG power in the delta frequency 
range. Indeed, the intraperitoneal injection of pentobarbital (40 mg/kg) 
produced LORR lasting about 55 min, and muscle relaxing effects. 
In the EEG spectra, the LORR induced by pentobarbital was associated to 
the wake EEG power spectra, with an increase in the delta and a reduction 
in the theta and alpha activity. 
Pentobarbital is a rapidly acting barbiturate. Barbiturates are agonists of the 
GABAA-receptor complex, and the combinations of PEA with this 
barbiturate exhibit synergistic interactions. In this study PEA, prolonged 
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twice the duration of the LORR induced by pentobarbital. The effects of 
PEA on LORR and EEG parameters were not reported previously in mice. 
From our experiments, it appears that a single administration of PEA did 
not produce any noticeable change in LORR and EEG activity in these 
mice. Instead, analysis of the experimental results in which PEA was co-
administered with pentobarbital revealed that mice showed an elongation of 
LORR time in comparison with mice administrated only with 
pentobarbital. 
Also the EEG frequencies in LORR changed in presence of PEA and 
pentobarbital: higher EEG power in the low-frequency band (0.5–4 Hz), 
and a lower EEG power in the 4–8 Hz frequency band relative to 
pentobarbital alone. The magnitude of EEG slow wave activity during 
LORR (0.5–4 Hz, SWA) is considered an indicator of LORR intensity 
(Daan et al., 1984; Tobler and Borbely, 1986). The increase of the 4–8 Hz 
frequency band PEA-induced suggested that PEA is involved in the 
modulation of pentobarbital-induced LORR. EEG theta activity has been 
linked to motor activity (Brown and Shryne, 1964; Franken et al., 1998). 
Thus, the highly significant decrease in theta activity after PEA 
administration may be related to the impairment of motor activity. 
The results of EEG analysis spectra showing an increase of slow-wave 
activity (EEG power density in the range 0.5-4Hz) and a concomitant 
reduction in frequencies above 15 Hz suggests that PEA, successfully 
increased the intensity of LORR by producing a reduction of motor 
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activity. 
The results of this study also showed that during pentobarbital-induced 
LORR, the power of alpha (8-13 Hz) and beta (13-18 Hz) frequency waves 
changed; in particular the results indicate that PEA is involved in the higher 
beta and lower alpha frequency bands in LORR. 
PEA administration leads to a different sleep-wake EEG activity in mice, 
probably reflecting variable effects on LORR-promoting and maintaining 
neuronal networks. We believe that administration of PEA might modulate 
the hypnotic effect evoked by pentobarbital modifying molecular 
mechanisms involved in pentobarbital effect. 
It is well known that pentobarbital positively modulates GABAA receptor 
and its hypnotic activity can be modulated by various factors, such as stress 
and several endogenous molecules. Neurosteroids are involved in a variety 
of brain functions, such as learning and memory, psychiatric mood 
disorders and behavioural abnormalities. Among neurosteroids, only ALLO 
and its 3-α,5-β stereoisomer pregnanolone positively and/or allosterically 
modulate GABA or pentobarbital actions at GABAA receptors at low 
nanomolar concentrations (Paul and Purdy, 1992; Puia et al., 2003) 
increasing both the probability and the frequency of chloride channel 
opening (Twyman and Mcdonald, 1992; Macdonald and Olsen, 1994). It 
has also been demonstrated that ALLO has somnogenic properties that are 
very similar to those of other GABAA modulators, especially of short-
acting benzodiazepines (Lancel et al., 1997; Damianisch et al., 2001), and 
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it may be considered an efficacious modulator of sleep-wake behaviour. 
Moreover, ALLO itself displays anxiolytic, sedative, hypnotic, analgesic 
and anaesthetic properties (Rupprecht et al., 2001). 
Here, we report that the increase of pentobarbital-induced LORR duration 
produced by PEA was linked to an increase of ALLO production. 
In our experimental conditions, ALLO increases pentobarbital-induced 
LORR time only at the highest dose used (30µg). Interestingly, when 
inactive doses of ALLO and PEA (1 µg, respectively) were co-
administrated a significant additive effect was shown, inducing a two-fold 
increase of pentobarbital-induced LORR time. This evidence suggests an 
additional role of exogenous ALLO on PEA activity in our experimental 
and time conditions. 
Hypothesizing the role of the de novo synthesis of ALLO in PEA effect, we 
used the inhibitor of 5-α reductase (FIN), reducing the availability of 5-α 
reduced neurosteroids including ALLO. As expected, the inhibitor reverted 
the PEA effect on pentobarbital-induced LORR duration. To confirm our 
observation, we then measured ALLO content in the brainstem evidencing 
the PEA capability to increase ALLO concentrations in this area already 
15-30 min after co-administration of PEA and pentobarbital. 
The biosynthesis of steroids in all steroidogenic tissues studied to date 
begins with the enzymatic conversion of cholesterol to pregnenolone. This 
reaction is catalyzed by CYP450scc, which is located on the matrix side of 
the inner mitochondrial membrane. 
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Here, we reported data indicating that PEA-induced increase in ALLO 
biosynthesis is related to an increase of CYP450scc expression, evidenced 
in ex vivo by western blot analysis, and in vivo using the inhibitor of 
CYP450scc, AMG. 
Although the rate-limiting step of steroidogenesis was previously thought 
to be the production of pregnenolone, the true rate-limiting step in this 
process is the delivery of cholesterol to the inner mitochondrial membrane 
where the CYP450scc is located (Lambeth et al., 1987; Privalle et al., 
1987; Miller, 2008). 
It was recently discovered that StAR, localized in mitochondria, is a critical 
protein in the regulation of cholesterol availability in the mitochondria of 
peripheral and central steroidogenic cells (Stocco, 2001 a; King et al., 
2002, Sierra, 2004). StAR is synthesized as a 37-kDa preprotein that is 
rapidly imported into the mitochondria, and processed to the inactive 
mature 30-kDa form found in the mitochondrial matrix. The C-terminal 
region contains a hydrophobic pocket that might be involved in the 
‘desorption’ of cholesterol from the sterol-rich outer membrane to the 
sterol-poor inner membrane. The N-terminal domain targets StAR in the 
mitochondria, and its cleavage effectively terminates the delivery of 
cholesterol to CYP450scc and therefore the synthesis of pregnenolone 
(Stocco, 2001 b; Bose et al., 2002; Mathieu et al., 2002; Thomson, 2003). 
In our experimental conditions both at 15 and 30 minutes after 
pentobarbital, PEA increased StAR (30-kDa) expression, suggesting an 
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augmentation in mitochondrial cholesterol import after PEA treatment. 
Based on these evidence, the increase of StAR and CYP450scc induced by 
PEA could act in a coordinated manner to induce steroidogenesis and in 
turn ALLO level augmentation. Further studies may identify other StAR-
independent mechanisms, such as START proteins or the peripheral 
benzodiazepine receptor, in PEA effect. 
We have, furthermore, contemplated the possibility that PEA could extend 
pentobarbital-induced LORR time in mice by increasing endocannabinoid 
levels in the CNS as suggested by Benn-Shabat (Benn-Shabat et al., 1998), 
since anandamide causes a cataleptic effect in mice (Sulcova et al., 1998). 
Hence, we used rimonabant, a CB1 receptor antagonist, which did not 
modify the effect of PEA, excluding the involvement of cannabinoid 
system in the central effect of PEA here reported. 
Recently, we demonstrated that rapid analgesic effect of PEA is related to 
an increased potassium efflux (Lo Verme et al., 2006). In light of this 
observation, we have also explored the possibility that PEA, by increasing 
potassium efflux, might indirectly cause an improvement of pentobarbital-
induced chlorum-dependent hyperpolarization. Both charybdotoxin and 
iberiotoxin, two different and selective KCa channel blocker failed to 
modify PEA effect on pentobarbital-induced LORR, suggesting that effect 
here described was independent of potassium channel increase outward 
conductance. 
Finally, our results provide a framework to better understand the role of this 
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naturally occurring fatty-acid ethanolamide in the CNS, expanding our 
previous observation about its role in controlling pain and inflammation. 
Here we report, for the first time, that pharmacological stimulation of 
central PPAR-alpha receptor by endogenous or synthetic agonist could 
positively modulate pentobarbital-induced LORR at least in part by the 
increase of central ALLO production. 
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